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Abstract: 
Due to the heart’s poor regenerative ability, new treatments need to be developed in order 
to repair damaged cardiac tissue after cardiac arrest. A common approach is to deliver 
adult stem cells combined with injectable hydrogels using minimally invasive surgery to 
the affected area. However, these studies have shown significant attrition of injected 
cells, attributed to hydrogel instability, nutrient and oxygen deficiency, and poor 
mechanical strength of the hydrogel. In addition, the injectable hydrogel must be able to 
support stem cell differentiation and long term survival of stem cells. An injectable 
chitosan-gelatin hydrogel has been developed to combat these challenges. To increase 
stability, gelatin was crosslinked with transglutaminase, an enzyme commonly used as 
meat glue in the food industry. To address the nutrient and oxygen deficiency, growth 
medium (nutrient source during in vitro culture) and oxygen releasing molecules have 
been added to the hydrogel. The mechanical strength of the hydrogel was manipulated to 
match cardiac tissue by varying the concentrations of the different polymers present in 
the hydrogel. This injectable hydrogel was seeded with human adipocyte stem cells and 
evaluated for viability of these cells. This hydrogel was able to retain cells inside the 
hydrogel without killing a significant population of the embedded cells for 21 days. 
Differentiation of human adipocyte stem cells did not occur for cells embedded in the 
hydrogel. Chemical stimulants and mechanical properties were not enough to induce 
differentiation. However, if this hydrogel were to be used for in vivo studies, the cardiac 
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Americans are newly diagnosed with a heart attack every 34 seconds (Members et al., 
2012). A heart attack, myocardial infarction (MI), occurs when the blood flow to the heart 
is blocked. This causes the cardiac cells to undergo a series of events that end in cell death 
due to the hypoxic environment (Konstantinidis et al., 2012). The remaining viable cells 
enlarge to make up for the work of the dead cells (Cleutjens et al., 1999, Konstantinidis et 
al., 2012). When cells enlarge, they experience more stress and increases the risk of the 
patient experiencing another heart attack. The life expectancy of a heart attack patient is 5-
10 years. If the patient arrives at the hospital and doctors diagnose the patient with a heart 
attack, they will administer different treatments to restore blood flow and prevent any 
further damage (Page, 1999). After the heart attack occurs, the “treatments” urge the patient 
to live a healthier life style by losing weight, eating a more nutritional diet, exercising 
regularly, eliminating alcohol and tobacco consumption; but do nothing to repair the actual 
damage in the cardiac tissue  (Page, 1999). Researchers are working on developing cell 
based therapies to repair the damage using stem cells (Behfar et al., 2014, Campbell and 




alone cannot repair the tissue.  Studies have shown that an injection of stem cells to the 
damaged region is not successful because the majority of the implanted cells (~90%) die 
within 1 week (Behfar et al., 2014, Menasche, 2011a, Segers and Lee, 2008). Cell death is 
hypothesized to be caused by lack of distribution, nutrients, and oxygen. With this 
knowledge, researchers are using biomaterials to deliver the stem cells to the damaged 
region in order to improve the chances of repairing the cardiac tissue. However, even with 
the addition of biomaterials, improvement in cell survival upon delivery was minimal 
(Hong et al., 2007).  While the addition of biomaterials resolved the issue of distribution, 
it brought upon new obstacles. Obstacles that are associated with the addition of 
biomaterials include: stability of material, immune reaction by the host, and mechanical 
property compatibility. The focus of this dissertation was to develop a cell based therapy 
that addresses the issues of lack of nutrients, lack of oxygen, material stability, mechanical 
property compatibility, and immune reaction by the host. To address these challenges, the 
project was divided into three aims. 
1.1 Aim 1: Develop hydrogel that can withstand wound healing environment and 
improve cell survival 
The purpose of this aim was to develop a hydrogel with mechanical properties similar to 
cardiac tissue and that is mechanically stable when exposed to a wound healing 
environment. To simulate a wound healing environment, hFF-1 were cultured for seven 
days in a chitosan-gelatin hydrogel. Previously, hFF-1 have been shown to release a 
significant amount of MMP-2 and MMP-9 when cultured on gelatin scaffolds. In order to 
address the challenges presented above, additional components such as growth medium, 




added to the hydrogel and their effects on mechanical properties and cell retention and 
viability were assessed.  The formulation that most resemble cardiac tissue, in terms of 
compressive modulus, was found to have a compressive modulus of 41.65 ± 4.07 kPa.  
Cell viability experiments showed a 2.5 times improvement in cell retention and viability 
in DOX with TG cross-linked CG hydrogels after seven days.  Stability of the hydrogel 
improved by adding TG and doxycycline encapsulated in PLGA.  Levels of MMP-2 and 
MMP-9 activity decreased after exposure to hydrogels containing DOX nanoparticles. 
1.2 Aim 2: Improve the survival of hASCs after application and evaluate 3D 
differentiation.   
For regeneration of functional cardiac patch, cardiomyocytes are needed to repair the 
cardiac tissue.  Using autologous sources would help minimize complications related to 
immunotherapy related to allogeneic cells.  Using adult stem cells harvested from 
specific patients would help in this regard.  Liposuction is used to remove excess adipose 
tissue which used to be discarded until identification of useful hASCs using collagenase 
and other chemicals (Zuk et al., 2001).  The hASCs extracted from the adipose tissue 
should differentiate into cardiomyocytes.  There are many factors that affect the 
differentiation process (Hwang et al., 2008).  Current methodologies differentiate hASCs 
in a 2-D environment using 5-azacytidine and laminin (Chang et al., 2012, van Dijk et al., 
2008).  To test whether differentiation can occur in a 3D environment, cardiomyogenic 
growth medium and laminin were incorporated into the hydrogel and hASCs 
differentiation was tested.  First, differentiation of hASCs was assessed in 2-D cultures 
using i) phorbolmyristate acetate (PMA), a protein kinase C activator for in nine days 




Expression of genetic markers present in hASCs and not in cardiomyocytes (CD105 and 
CD144) after hASCs were assessed either by flow cytometry, immunohistochemistry, or 
qPCR.  This suggests that differentiation was successful in 2-D environment containing 
5-azacytidine and laminin.  Next, hASCs were cultured in the hydrogel containing 5-
azacytidine and laminin for up to three weeks and viability and retention was assessed 
similar to Aim 1.  Addition of 5-azacytidine and laminin to the hydrogel decreased the 
viability to nearly 70% after 21 days.  This could be attributed to the long term exposure 
to 5-azacytidine.  In any case, the presence of hASCs markers were confirmed by 
immunohistochemistry at the end of 21 days, suggesting differentiation was not 
successful in 3-D environment.  In summary, this hydrogel is able to support stem cell 
culture for three weeks but does not induce differentiation of adipocyte stem cells into 
cardiomyocytes.   
1.3 Aim 3: Addition of oxygen releasing component in hydrogel formulation and 
investigate hydrogel’s differentiation ability and mechanical properties.  
When hydrogels along with cells are injected into the cardiac tissue, they are in a hypoxic 
environment.  In order to address oxygen requirement and improve viability, oxygen 
releasing molecule, calcium peroxide (CaO2), was added during the hydrogel preparation.  
However, CaO2 is alkaline and alters the pH of the solution.  Since the injectable 
hydrogel preparation is pH sensitive, hydrogel formulation needs to be adjusted in order 
to maintain the characteristics of temperature sensitive gelation.  In this aim, first I 
optimized the hydrogel preparation methodology with the inclusion of CaO2.  Measured 
mechanical properties (compressive, tensile, cyclical and relaxation) showed significant 




appeared to be quicker relative to the culture duration of stem cells.  Also, amount of 
CaO2 that could be added to the hydrogel is limited by i) solubility and ii) pH change.  In 
order to increase the amount of CaO2 to prolong the release of oxygen, different methods 
of encapsulation were tested.  Encapsulation of calcium peroxide was unsuccessful, but 
addition of CaO2 despite improved the mechanical properties.  Viability studies showed 
that addition of CaO2 resulted in a decrease in cell viability.  Differentiation studies 
showed the presence of hASCs markers were confirmed by immunohistochemistry at the 
end of 21 days, suggesting differentiation was not successful in 3-D environment.  In 
summary, this hydrogel is able to support stem cell culture for three weeks but does not 
induce differentiation of adipocyte stem cells into cardiomyocytes.  
1.4 Summary 
This investigation is focused on developing an injectable hydrogel for use in conjunction 
with hASCs to repair large cardiac necrotic regions.  Several obstacles were addressed in 
order to increase the probability of success when this treatment is used in vivo.  The 
hydrogel formulation was optimized to mimic the mechanical properties of cardiac tissue. 
To avoid immune rejection by the host, I propose using the patient’s own adipocyte stem 
cells. According to Iacobellis, obese people are more likely to experience a heart attack 
and to survive the attack (Iacobellis, 2009).  Therefore, there is a high probability that the 
patient receiving this treatment will benefit from liposuction surgery and the waste 
adipose tissue can be used to obtain adipocyte stem cells that will not be rejected by the 
patient’s immune system.  If treatment is successful, the quality of life may improve for 







2.1 The biology of the heart and heart attack 
 
Cardiac tissue regeneration has been investigated for more than 150 years (Laflamme and 
Murry, 2011), because the heart is responsible for the transportation of blood throughout 
the body; without proper function death is imminent. Heart disease is the number one cause 
of death in the world, approximately 17.3 million deaths per year with 600,000 deaths in 
the United States alone (Mendis et al., 2011, Kochanek et al., 2011). Latinos and Hispanics, 
unfortunately, have even higher risks compared to the average American because of high 
blood pressure, obesity and diabetes (Go et al., 2013). According to the American Heart 
Association (AHA), in 2008 coronary heart disease accounted for 50% of heart disease 
related deaths and the cost of coronary heart disease (including hospital discharge, 
medications, operations, etc.) was estimated to be $190.3 billion (Roger et al., 2012). In 
2010, it is estimated that 7.6 million people experienced a heart attack, and 125,000 
resulted in death (Go et al., 2013). There are many heart-related diseases that cause damage 
to the cardiac tissue. For example, myocardial infarction (MI or commonly referred as heart 
attack) can cause necrosis to a large number of cardiac myocytes (heart cells) 




coronary arteries to the heart is obstructed which halts the continuous supply of oxygen to 
the heart tissue resulting in the death of cardiomyocytes within two minutes of being 
deprived of oxygen (Randall and Romaine, 2005).  Hypertension (high blood pressure) can 
cause cardiac  tissue damage over the course of many years asymptomatically (Mendis et 
al., 2011). Aging causes cardiac tissue damage via deterioration; nearly 1 gram of cardiac 
tissue is lost every year even in the absence of heart disease (Olivetti et al., 1991).  Upon 
diagnosis for increased risk of a MI, treatments such as oxygen therapy and ingestion of 
blood thinners, nitroglycerin, and chest pain relievers are administered.  Once the diagnosis 
of a MI is confirmed, treating the formed plaque is considered based on percentage of 
blockage (Page, 1999).  The most common treatments are “clot-busting” medicines and 
percutaneous coronary intervention (PCI) (Page, 1999).  The patient can reduce the risk of 
recurrence of heart attacks by following a healthy diet, maintaining a healthy weight and 
exercise regimen, and curbing habits such as cigarette smoking and drinking alcohol (Page, 
1999, Roger et al., 2012, Randall and Romaine, 2005, Mendis et al., 2011, Go et al., 2013).  
These treatments are preventive measures rather than repairing the damaged region of the 
heart tissue. 
Many parts of the human body including skin and bone can regenerate after a small 
injury or fracture.  Whether cardiac tissue regenerates after major cardiac tissue damage 
is still a controversial topic, despite some evidence of remodeling activity (Cleutjens et 
al., 1999).  In general, the remodeling process of cardiac tissue is described to occur in 
four phases (Cleutjens et al., 1999).  Phase 1 is the death of cardiac myocytes (also 
referred as cardiomyocytes) either due to necrosis (characterized by swelling of the cells) 




apoptotic cells cannot be phagocytized by neighboring cells and remain in the heart 
tissue, which triggers phase 2, acute inflammation (Cleutjens et al., 1999).  This 
inflammatory response causes migration of granulocytes which are responsible for 
removing the dead cells from the damaged area.  After successful removal of the dead 
cells, new extracellular matrix proteins are being deposited in the damaged area.  Phase 3 
is granulation tissue formation, which increases the tensile strength of the damaged area 
and prevents the cardiac tissue from rupturing (Cleutjens et al., 1999).  In addition, the 
granulation tissue undergoes angiogenesis, which is essential for wound healing.  A 
mature granulation tissue (2-3 weeks old) consists of partly cross-linked collagens, 
macrophages, blood vessels, and myofibroblasts.  Phase 4 is scar formation.  At this point 
the majority of cells, except myofibroblasts, undergo apoptosis and the collagen fibers are 
fully cross-linked (Cleutjens et al., 1999).  
In summary, these remodeling stages do not recruit a large number of new cells, instead 
they increase the size of the existing cells and increase the amount of stress the individual 
cell experiences. This puts the patient at a greater risk of developing another heart attack 
and thus not a very effective and reliable method of injury repair. Many scientists have 
been working on repairing the damage with additional cells so that the amount of stress 
on individual cells is reduced and thus lowers the risk of having another heart attack.  
2.2 Repairing the damage with cells 
Terminally differentiated cells (such as cardiac myocytes) are needed to repair and 
repopulate a damaged area.  Cardiac cells are difficult to harvest and grow in vast 
quantities. Therefore, due to a limited quantity of terminally differentiated cardiac 




intriguing alternative because theoretically, stem cells can differentiate into cardiac cells 
(Bollini et al., 2011, Young et al., 2011). Stem cells are precursor cells that give rise to 
different cell lines. The process of which a stem cell converts into a different cell type is 
called differentiation. In addition to different differentiation capabilities, there are 
different types of stem cells (Chong et al., 2014, Keefer and Desai, 2011, Hwang et al., 
2008, Heng et al., 2004, Dawson et al., 2008).  Embryonic stem cells are found in the 
embryo and are known to be pluripotent, meaning they can differentiate into any type of 
cell.  However, to harvest embryonic stem cells one must destroy the blastocyst, which 
raises ethical issues on when does life start. Due to ethical issues, many researchers have 
avoided using human embryonic stem cells. 
On the other hand, mesenchymal stem cells (MSCs) have societal acceptance but are not 
pluripotent and proliferate less than embryonic stem cells (Li et al., 2007, Zuk et al., 
2001, Richardson et al., 2008, Lindroos et al., 2011, Elnakish et al., 2012).  They can 
differentiate into lineage-related and also some cell types from different lineage.  
Obtaining a large number of adult stem cells is difficult (Segers and Lee, 2008), but they 
can be found in adult tissues, including bone marrow, umbilical cord, and adipose (fat) 
tissue (Bosi et al., 2005, Menasche, 2011a, Segers and Lee, 2008, Lindroos et al., 2011).  
Availability of MSCs is abundant due to the prominence of bone marrow registries, but 
there is concern about immune response and rejection of transplanted cells. Autologous 
stem cells harvested from the patient being treated can minimize the need for 
immunosuppression therapies post-implantation.  Currently, most FDA approved stem 
cell based therapies use MSCs derived from the bone marrow (Bosi et al., 2005, 




isolation is painful and harvest number is low (Kern et al., 2006). As previously 
mentioned, another source for stem cells is fat tissue (Kern et al., 2006, Young et al., 
2011, Zuk et al., 2001, van Dijk et al., 2008, Lindroos et al., 2011, Choi et al., 2010). Due 
to the advances of plastic surgery, specifically liposuction, harvesting adipocyte stem 
cells is simple and quick. Adipose tissue derived stem cells were shown to differentiate 
into various cell types including heart cells (Zuk et al., 2001).  Recently, a small 
population of stem cells residing the heart has been discovered. These stem cells have 
been called cardiac stem cells (CSCs) (Bearzi et al., 2007). These discovery is still recent 
and protocols regarding isolation are still being developed. Therefore, for this study, I 
used human adipocyte stem cells that are commercially available.  
Cardiomyogenesis is the process where a stem cell differentiates into a cardiomyocyte.  
Cardiomyocytes can be differentiated from stem cells and have been  explored to 
regenerate cardiac tissue (Emmert et al., 2014). Differentiation can be induced by a 
number of conditions including, mechanical stimulus, electrical stimulus, or chemical 
stimulus (Happe and Engler, 2016, Bollini et al., 2011, Menasche, 2011a, Hidalgo-
Bastida et al., 2007, Leor et al., 2005, Guo et al., 2006, Keefer and Desai, 2011, Hwang et 
al., 2008, Heng et al., 2004, Dawson et al., 2008, Choi et al., 2010). Recently, 
cardiomyogenesis in hASCs has been investigated with many different techniques and 
different results.  The best technique is the one that produces cells with cardiac receptors 
and produces beating heart cells.  One of the most popular techniques is to culture hASCs 
with rat neonatal cardiomyocytes (Choi et al., 2010).  Within 1 week, hASCs were 
beating and expressing high levels of cardiac receptors (Choi et al., 2010).  The main 




and is therefore limited only to a non-clinical setting.  Another technique to induced 
cardiomyogenesis is to expose the cells to 5-azacytidine (AZA) with and without laminin.  
AZA has successfully induce cardiomyogenesis in both animal and human adipocyte 
stem cells.  However, beating heart cells have not been observed (Choi et al., 2010, Wan 
Safwani et al., 2012).  A research group decided to culture hASCs on top laminin and 
stimulate them with AZA (van Dijk et al., 2008).  While morphological changes were 
observed, no beating cells were found.  Another stimulant that has been investigated for 
cardiomyogenesis is phorbolmyristate acetate (PMA), a protein kinase C activator 
(Chang et al., 2012).  This research group reported the presence of mRNA that indicated 
cells underwent cardiomyogenesis in 6 days.  However, no results have been published 
using the mentioned techniques and there is no mention of morphological changes and 
beating cells.  There are many other techniques that claim to induce cardiomyogenesis 
but they all have disadvantages.  I decided to focus on 5-azacytidine due to multiple 
sources confirming differentiation of hASCs into cardiomyocytes by expression of 
cardiac markers.  
With the increased availability of various cell sources, the focus has shifted towards 
methods to deliver those cells to the needed area in the heart.  Cells that are transplanted 
into the heart have to integrate with the native tissues and align with the preexisting tissue 
pattern.  In addition to alignment of cells, cell survival and distribution is a major 
drawback of delivering stem cells alone to the affected area. This is due to the delivery 
mechanism by which the cells are delivered.  Cells are delivered by a syringe, and 
therefore millions of cells are clustered into a small space.  This means that cells will be 




transplanted into the area are dead within a week (Behfar et al., 2014, Menasche, 2011a, 
Segers and Lee, 2008).  Since delivering a pellet of cells does not ensure the alignment, 
survival, and distribution of cells, biomaterials with appropriate properties are needed, 
which is the focus of the next section.  
2.3 Scaffold based tissue engineering 
There are four major approaches to delivering cells to the heart: intracoronary, 
intramyocardial, intravenous, and epicardial attachment (Campbell and Suzuki, 2012).  
Intracoronary injection induces little inflammatory response but does not allow for cell 
attachment.  Intramyocardial injection allows for adult stem cell delivery to a specific 
area, but in the process causes inflammation, mechanical injury, and cell clusters.  
Intravenous injection is the most common route for delivery but location specificity is a 
concern along with cell attachment.  Epicardial attachment of biomaterials allows for 
better cell attachment than other routes, but limited cell migration is an issue.  There is no 
clear preferred route since each has its own advantages and disadvantages.   
Biodegradable scaffolds are used to provide a temporary substrate to seeded cells and 
support tissue regeneration either in situ or in vitro (Emmert et al., 2014).  Seeded cells 
adhere and proliferate, migrate, and differentiate (Ratner, 2004).  The scaffold transiently 
degrades, leaving only the necessary healthy tissue.  There are two types of scaffolds: 
naturally occurring and manmade scaffolds, each with advantages and disadvantages.  
Naturally occurring scaffolds are obtained by decellurizing tissue from human or animal 
sources with the goal of repopulating them with stem cells (Moroni and Mirabella, 2014).  
Components of the extracellular matrices are generally conserved among species and are 




components are eliminated from tissues, rejection reactions can be prevented.  The main 
advantage of using decellularized tissue is that it structurally resembles the native tissue 
and therefore supports regeneration into functional similar tissue.  Decellularized 
scaffolds derived from porcine heart valves, human pericardium, and whole rat hearts 
have been used for cardiac tissue engineering (Vashi et al., 2015).  While this approach 
has been successful in repairing smaller and less complicated tissues, like the trachea and 
bladder, it is yet to be successful on larger and more complicated cardiac tissues.  Using 
decellularized tissue is constrained by obtaining reliable, reproducible products in large-
scale preparations and is subject to the concerns of heterogeneity in the structural features 
(Raghavan et al., 2005).   
An alternative option is forming manmade matrices with properties similar to the 
structure of a tissue to be replaced.  Manmade scaffolds can be further divided into two 
categories, preformed scaffolds and hydrogels. Manufacturing preformed porous 
scaffolds using pure components allows formation of matrices with required features in 
addition to large scale production (Oh et al., 2009, Madihally and Matthew, 1999a, Kim 
and Mooney, 2000, Leor et al., 2005, Dawson et al., 2008, Amir et al., 2009).  Further, 
advances in nanotechnology have made possible technology to control the tissue 
regeneration via delivery of essential factors.  Significant advances have been made in 
fabricating porous scaffolds from biodegradable polymers (Lawrence et al., 2009, Li et 
al., 2005, Huang et al., 2006).  The porous structure may be modified post-fabrication by 
inclusion of nanoparticles or etching the surface of the matrix.  Generating a porous 
scaffold is done either by additive processes such as bioprintring, and electrospinning, or 




and gas foaming techniques (Hong and Madihally, 2011).  The scaffold’s properties can 
be manipulated via selection of biocompatible materials, solvents used, and processing 
methods.  To recreate the native architecture, scaffolds should guide similar cellular 
alignment and deposition of de novo synthesized matrix components (Happe and Engler, 
2016).  In summary, biomaterials or delivery of cells alone is not enough to regenerate 
the tissue. The combination of both biomaterials and stem cells need to combine to 
regenerate the damaged tissue. Additionally, the delivery route of the implantation of a 
scaffold needs to be considered. For example, performing an open heart surgery allows 
the surgeon to transplant the scaffold to the affected area with ease. However, open heart 
surgery is a complicated surgery and not everyone is able to withstand a major surgery 
like that. Therefore, another type of scaffold needs to be considered (hydrogels) to 
increase the population of potential patients that are able to be treated with a therapy that 
uses both biomaterials and stem cells. The next section will cover hydrogels and how 
they can be easily transplanted using less complicated surgery. 
2.4 Hydrogel fabrication 
The main disadvantage of pre-formed scaffolds is the delivery route, which requires the 
use of major invasive surgery.  Injectable hydrogels offer a minimally invasive 
alternative for arthroscopic surgeries and ease of incorporation of cells and bioactive 
agents.  Hydrogels are water-swollen, cross-linked polymeric structures held together by 
chemical bonds and/or van der Waals forces (Ratner, 2004, Enderle and Bronzino, 2012, 
Slaughter et al., 2009).  Hydrogels can be specifically designed to respond to different 
environmental factors such as temperature, radiation, pH, chemical agents, etc.  There are 




blend hydrogels (Rafat et al., 2008, Lawrence et al., 2009, Saha et al., 2007, Hodde, 
2002, Dawson et al., 2008).  Natural hydrogels are composed of naturally derived 
polymers such as chitosan, collagen, gelatin, cellulose, fibrinogen, etc.  Hydrogels based 
on natural polymers are biocompatible, biodegradable, have high cell adhesion, and 
resemble the native ECM structure (Li and Guan, 2011).  Disadvantages of using 
hydrogels based on natural polymers include weak mechanical strength, immune 
rejection (depending on the source of the polymer), slow gelation, fast degradation, and 
potential carcinogenic consequences (Li and Guan, 2011).  On the other hand, synthetic 
hydrogels are composed, as the name implies, of synthetic polymers such as polyethylene 
glycol, polyvinyl alcohol, polyglycolic acid, polylactic acid, etc.  Synthetic hydrogels can 
have fast gelation times and are commonly bio-inert, biocompatible, and easily 
manipulated to obtain desired mechanical properties (Li and Guan, 2011).  Disadvantages 
of using synthetic hydrogels include low cell adhesion, inability to deliver by injection, 
toxic crosslinking agents, non-biodegradability, and elastic modulus mismatch (Li and 
Guan, 2011). In summary, hydrogels are a better alternative because of their delivery 
method. Both natural and synthetic polymers have their disadvantages, therefore the 
choice of one over the other is based on what specific challenges are present in the 
disease that the treatment is for. For cardiac tissue regeneration, natural polymers are a 
better choice due to their molecular similarity to cardiac tissue. Next, I will be presenting 
the two polymers I chose as the foundation for the hydrogel investigated in this research 
project. 
2.5 Hydrogel’s components: chitosan, gelatin, and other polymers  




medium, calcium peroxide, 5-azacytidine, laminin, transglutaminase, and PLGA 
nanoparticles encapsulating doxycycline hyclate. Chitosan is obtained by deacetylation of 
chitin (Shigemasa Y, 1994), the second most abundant polymer occurring in nature, it 
also has other advantages such as low cost, and easy availability (Khor and Lim, 2003).  
Chitosan exhibits different physicochemical characteristics, i.e., MW, crystallinity, 
deacetylation and positive charge.  It is soluble in weak acids (pH<6.3) and can be easily 
processed into films and porous scaffolds of desired configuration (Madihally and 
Matthew, 1999a).  Chitosan is metabolized into non-toxic D-glucosamines by lysozymes 
(Mi et al., 2002, Tomihata and Ikada, 1997) and hence is biodegradable.  Lysozyme is an 
innate non-immunologic antibacterial enzyme and is one of the most structurally well-
characterized carbohydrate hydrolases (Kristiansen et al., 1998).  The three-dimensional 
structures of lysozyme in both the complexed and uncomplexed states have been 
established and the substrate binding sites are also known.  The lysozymal hydrolysis of 
chitosan is an acid catalytic reaction with a peak reaction rate occurring around pH 4.5 to 
5.5.  Chitosan can be processed into beads, gels, fibers, or films (Aiba S-i, 1987, Hirano 
S, v, Kikuchi Y, 1976), and has shown promise for a number of tissue engineering 
applications (Cai et al., 2002, Chung et al., 2002, Lahiji et al., 2000, Mizuno et al., 2003, 
Zhu et al., 2002). 
Chitosan hydrogels can be formed by either pH or temperature changes and by 
chemically crosslinking polymers.  Thermoresponsive hydrogels have been developed by 
combining a solution of deacetylated chitosan with β-glycerophosphate (Iyer et al., 2012).  
These hydrogels can be tailored to gel at body temperature while remaining in a liquid 




electrostatic charge of chitosan and therefore elevate the pH of the solution to biological 
condition (pH = 7.4) (Riva et al., 2011).  The poly-alcohol group of β-glycerophosphate 
shields the chitosan chain, accelerating the formation of a hydrophilic shell around the 
chitosan molecule, and thus improving the chitosan chain protective hydration.  This 
prevents chitosan from precipitating out with change in pH at low temperature.  
However, as the temperature is increased, hydrophilic interactions and hydrogen bonding 
interactions increase, triggering physical crosslinking throughout the whole solution, and 
starting the gelation process (Riva et al., 2011).  Chemically crosslinked hydrogels can be 
formed by covalently linking chitosan and another polymer (in this case poly-ethylene 
glycol, PEG) with the use of a crosslinking agent.  Dal Pozzo et al. reported that PEG-
dialdehyde diethyl acetals are suitable compounds for the crosslinking of chitosan and 
partially reacetylated chitosan (Dal Pozzo et al., 2000).  This is one of many example 
crosslinking methods for chitosan based hydrogels and scaffolds reported (Berger et al., 
2004, Ravi Kumar, 2000, Riva et al., 2011, Dal Pozzo et al., 2000).   
In order to overcome some of the limitations of chitosan, one approach is to blend with 
highly ductile PCL, along with gelatin, collagen, or other proteins (Table 2.1).  These 
additions function to improve the hydrogel performance by either increasing the 
mechanical strength, introducing cell binding sites, and/or tailoring the degradation rate.  
Some of the aforementioned polymers can be found in the extracellular matrix (ECM). 
ECM is mainly composed of proteoglycans and fibrous proteins. Fibrous proteins found 
in the ECM include: collagen, elastin, laminin, and fibronectin. Collagen is the most 
abundant fibrous protein in animals. Collagen’s main function is to provide tensile 




undergo repeated stretching, such as muscle fibers and cardiac tissue. Laminin and 
fibronectin play key roles in cell differentiation, migration, and adhesion.  The most 
abundant protein in the human body is collagen, which therefore makes this protein an 
excellent additive for chitosan hydrogels due to natural binding sites and cellular 
interactions.   
Table 2.1. Hydrogels of chitosan in combination with other molecules 
Molecule name pH neutralization method 
Collagen (Chiu and Radisic, 2011) PBS and NaOH  
Alginate (Deng et al., 2015) β-glycerophosphate  
RoY Peptide (Shu et al., 2015) β-glycerophosphate 
Gold nanoparticles and 
polyethylene glycol (PEG) 
(Brondani et al., 2014) 
Crosslinked with tetraethylene glycol dialdehyde, 
glycol dialdehyde diethyl diacetals, or 
tetraethylene glycol disuccinimidyl disuccinate 
Lactose and azidobenzoic acid 
(Fujita et al., 2005) Cross-linked by UV 
Lactic acid and methacrylic acid 
(Hong et al., 2007) Radical polymerization 
 
Gelatin is an inexpensive, nonirritating, biocompatible, and biodegradable protein derived 
from the hydrolysis of collagen.  Gelatin contains a peptide sequence that promotes cell 
attachment.  Gelatin is blended with chitosan via electrostatic interactions without 
additional chemical cross-linkers and porous scaffolds can be formed.  Cells exposed to 
gelatin-containing chitosan structures also show higher level of MMP-2 MMP-9 (Iyer et 
al., 2012), leading to premature degradation of the scaffold when higher number of cells 
are loaded.  This could lead to attrition of delivered cells prior to engraftment. 
Furthermore, in heart failure, MMP-9 plays a major role in the pathological remodeling 
of ECM (Tyagi and Joshua, 2014).  Whether cells are delivered by hydrogel, scaffold, or 




chitosan hydrogel, Hong et al. reported that the cell retention increased to 17.5% 
(compared to a 10% retention of cells delivered with no hydrogel) one week after 
implantation, and attributed this to the stability of the hydrogel (Hong et al., 2007).  
Premature degradation of scaffolds is one of the most challenging problems when 
designing cellular therapies to be used in conjunction with biomaterials. One easy way to 
get around the problem is to use synthetic non-biodegradable materials. However, these 
materials may not be optimal for some treatments. Therefore, most people choose to use 
naturally occurring polymers. Naturally occurring polymers generally have better 
cytocompatability and are easily degrade by the host compared to synthetic polymers. 
But being easily degradable can be an issue because fast degradation or premature 
degradation can lead to incomplete treatment and therefore ineffective. The enzymes 
responsible for premature degradation are called Matrix Metalloproteinase (MMP). 
MMPs are responsible for degrading proteins mostly present in the extracellular matrix 
(ECM). While most MMPs target ECM proteins, there are some that are involved in the 
processing of cytokines, chemokines, hormones, adhesion molecules, and membrane-
bound proteins. The involvement of MMPs in the processing of these molecules can lead 
to changes in normal cellular behavior, cell-cell communication, and tumor progression. 










MMP-1 Collagenase-1, interstitial collagenase, vertebrate collagenase 
MMP-2 Gelatinase A, 3/4 collagenase, 72kDa gelatinase, MMP-5, tissue gelatinase, type IV collagenase 
MMP-3 Stromelysin-1, collagenase activating protein, MMP-6, procollagenase activator, proteoglycanse, transin 
MMP-7 matrylysin, putative, metalloproteinase-1, uterine metalloendopeptidase 
MMP-8 collagenase-2, neutrophil collagenase 
MMP-9 Gelatinase B, 92 kDa gelatinase, macrophage gelatinase, neutrophil gelatinase, type IV collagenase, type V collagenase 
MMP-10 stromelysin-2, transin-2 
MMP-11 stromelysin-3 
MMP-12 macrophage elastase, metalloelastase 
MMP-13 AgMMP3 (Anopheles gambiense), collagenase 3, rat collagenase 
MMP-14 membrane type (MT) MMP-1, MT1-MMP, MTMMP-1 
MMP-15 membrane type (MT) MMP-2, MT2-MMP, MTMMP-2, SMCP-2 
MMP-16 membrane type (MT) MMP-3, MT3-MMP, MTMMP-3, ovary metalloproteinase 
MMP-17 membrane type (MT) MMP-4, MT4-MMP, MTMMP-4, MMP25beta (Brachydanio rerio) 
MMP-18 collagenase 4, xCol4 (Xenopus) 
MMP-19 RASI-1, RASI-6 
MMP-20 enamelysin 
MMP-21 XMMP (Xenopus) 
MMP-22 CMMP (Gallus domesticus), MMP-27 (Homo sapiens), matrix metallopeptidase 27 
MMP-23A  
MMP-23B cysteine-array matrix matalloproteinase, CA-MMP, MIFR protein (Homo sapiens),  MMP23A g.p. (Homo sapiens), femalysin 
MMP-24 membrane type (MT) MMP-5, MT5-MMP, MTMMP-5 
MMP-25 membrane type (MT) MMP-6, MT6-MMP, MTMMP-6, leukolysin 










While there are many MMPs, they can be separated into major groups when concerning 
degradation of biomaterials. One group is called Collagenases (MMP-1, MMP-8, MMP-
13, and MMP-19) and degrade fibrillary collagens in their native triple-helical 
supersecondary structure. Another group is called Gelatinases (MMP-2 and MMP-9) and 
degrades gelatin are known to be involved in inflammatory processes, tumor progression, 
and cardiovascular and autoimmune diseases. This section will focus on Collagenases 
and Gelatinases because the substrates that these groups encase are commonly used in the 
creation of biomaterials to be used in clinical applications and the inhibitor chosen for 
this therapy has been shown to reduce the activity of collagenases and gelatinases. 
High levels of MMPs can be observed during the process of tissue remodeling in a 
wound healing environment, especially during cardiac remodeling. (2008). A link has 
been associated between MMP activity and cardiac remodeling, specifically collagenases 
and gelatinases (2008). Cells that release these MMPs during cardiac remodeling include 
but are not limited to cardiomyocytes, cardiac fibroblasts, endothelial cells, vascular 
smooth muscle cells, neutrophils, and macrophages (2008). No single cell type is 
responsible for the production or release of all MMPs listed but there is overlap between 
them. Most biomedical treatments that are being developed will be exposed to MMPs 
when they are implanted in the body and therefore, be exposed to an environment that 
can cause the biomaterial to be prematurely degraded.  
To overcome premature degradation, two courses of action were taken. First course of 
action was to inhibit gelatinases, which are responsible for digesting gelatin chains. 
Second course of action is to naturally crosslink gelatin molecules with transglutaminase 




degradation, MMP-2 and MMP-9 activity must be inhibited. Inhibition of matrix 
metalloproteinases (MMPs) is not an easy task, as matter of fact the Food and Drug 
Administration (FDA) has only approved one single compound to be used as an MMP 
inhibitor as a safe and effective treatment. Doxycycline hyclate was approved in 1967 
and initially used as an antimicrobial agent. However, in 1989 the FDA approved 
doxycycline to be used as an inhibitor of collagenase for the treatment of periodontitis. 
Thus, making doxycycline the first and only MMP inhibitor to be approved by the FDA 
(Sang et al., 2006, Stechmiller et al., 2010). By no means does this mean that doxycycline 
is the only MMP inhibitor, in fact we now know the different types of MMP and their 
structures, activation mechanisms, degradation mechanisms, and functions. Doxycycline, 
has been shown to inhibit MMP-1, MMP-2, MMP-8, MMP-9, MMP-13 (Smith et al., 
1999, Liu et al., 2003). This inhibitor focuses on collagenase and gelatinases. A drawback 
of doxycycline has a half-life of 18-22 hours and therefore is only a temporary solution. 
The best solution would be to slowly release doxycycline over a prolonged period of time 
until the treatment has had enough time to display positive results, such as successful 
migration of implanted cells, regeneration of tissue, angiogenesis, etc. Extended release 
of doxycycline has been achieved by encapsulating doxycycline in PLGA-PCL 
microparticles (Mundargi et al., 2007). 
In order to further increase mechanical stability and decrease degradation rate, addition of 
transglutaminase (TG) was investigated. TG (EC 2.3.2.13) catalyzes Ca2+-dependent 
transamidation of proteins and formation of protein polymers via protease-resistant 
covalent isopeptide bonds, which are approximately twenty times stronger than hydrogen 




the formation of the amide crosslink from γ-carboxamide and primary amine 
functionalities (Aeschlimann and Paulsson, 1994).  Calcium-independent TG is typically 
used in the crosslinking in gelatin, yogurt, meat and fish analogues (surimi) (Lim et al., 
1999, Joseph et al., 1994).  TG containing hydrogels are used as adhesives and for in 
vitro expansion of cells (Jones and Messersmith, 2007).  Gelatin cross-linked with TG is 
used in forming in situ gel adhesives and is very promising as a hemostatic surgical 
sealant for soft tissues (Liu et al., 2009).  
The hydrogel in this research project was be exposed to a nutrient and oxygen deficient 
environment. In order to address the hypoxic environment of the ischemic heart, oxygen 
releasing molecules such as sodium percarbonate, calcium peroxide, magnesium 
peroxide, hydrogen peroxide, and fluorinated compounds could be helpful (Camci-Unal 
et al., 2013).  For this project, calcium peroxide was chosen because of the compounds 
slower release rate of oxygen. Oh et al has shown that cells cultured on a PLGA scaffold 
with calcium peroxide particles can survive for 10 days in a hypoxic environment (Oh et 
al., 2009). However, when calcium peroxide is dissolved in acidic conditions (needed to 
dissolve chitosan), pH changes can occur and the presence of calcium could cause 
chelation and destabilization of the hydrogel.  To supplement this environment with 
nutrients, powdered growth medium was added. Growth medium is used in in vitro 
conditions to supplement cells with nutrients needed for growth and proliferation.  
In summary, for this therapy to be successful, it needs to increase the survival rate of 
stem cells that are embedded in the hydrogel and implanted in the heart. To do this, we 
looked at the drawbacks of chitosan and gelatin and addressed them. For example, 




and MMP-9 activity, therefore doxycycline and TG were added. The environment where 
the hydrogel was to be implanted was also considered. This environment is high on 
MMP-2 and MMP-9, and low on nutrients and oxygen. Growth medium and calcium 
peroxide were added to increase nutrients and oxygen concentration. Finally, to ensure 
that the embedded stem cells differentiate into cardiomyocytes, a stimulating agent was 







IMPROVING THE STABILITY OF CHITOSAN–GELATIN-BASED HYDROGELS 
FOR CELL DELIVERY USING TRANSGLUTAMINASE AND CONTROLLED 




In this study, we hypothesize that inhibiting MMP activity during the initial phase of post-
cell delivery improves the stability of the chitosan-gelatin (CG) hydrogels, while long term 
stability and mechanical property can be improved with a slow enzymatic cross-linking 
using transglutaminase (TG), and adding nutrients to the hydrogel formulation would 
address nutrient requirements (Broderick et al., 2005, McDermott et al., 2004).  TG is 
found in most living organisms, and its functions include blood clotting and liver 
detoxification (Greenberg et al., 1991).  Calcium-independent microbial TG (mTG) is 
popularly used in the covalent crosslinking of gelatin between glutamine and lysine 
residues (Lim et al., 1999, Joseph et al., 1994).  mTG containing hydrogels are used in 
forming in situ gel adhesives and for in vitro expansion of cells (Jones and Messersmith, 
2007).  




mTG increases the mechanical strength of gelatin-based hydrogel (Aeschlimann and 
Paulsson, 1994), and mTG cross-linked gelatin is very promising as a hemostatic surgical 
sealant for soft tissues (Liu et al., 2009).  However, TG in high concentrations is toxic 
and causes cell death, leading to concerns on cytotoxicity (Broderick et al., 2005). MMP-
2 activity in fibroblasts is regulated by the mechanical strength of hydrogels (Tomasek et 
al., 1997).  An overexpression of MMP-2/9 results in premature degradation of the 
hydrogel and loss of cells.  One approach to inhibiting MMP-2/9 activity is using 
doxycycline (DOX), a member of tetracycline family of drugs known for antibiotic 
properties.  Independent of antibacterial activity, it is tested in numerous conditions 
associated with elevated ECM degrading enzymes, including arthritis and chronic 
wounds management (Newby, 2012).  Since serum half-life of DOX is 18-22 hours 
(Agwuh and MacGowan, 2006), we approached encapsulation of DOX in PLGA 
nanoparticle prior to mixing in the hydrogel.  Experiments were performed to evaluate 
the approach in vitro using fibroblasts.  Furthermore, mechanical properties were 
determined to assess whether TG added in the hydrogel would cross-link gelatin, increase 
mechanical stability, and thus decreasing the rate of degradation.  These results show 2.5 
times improvement in cell retention and slow release rate of DOX with TG cross-linked 
CG hydrogels. 
3.2. Materials and methods 
3.2.1. Sources for Materials. 
Low MW chitosan (50 kDa and 75-85% deacetylation), gelatin type A (300 Bloom), β-
glycerophosphate (2GP), 50:50 poly lactic-co-glycolic acid (PLGA, 110 kDa), polyvinyl 




pharmaceutical secondary standard) and bovine serum albumin (BSA) were procured 
from Sigma Aldrich Co (St. Louis, MO).  Phosphate buffer solution (PBS, pH=7.4), 5-
(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE) - mixed isomers, 
and powdered DMEM low glucose were procured from Life Technologies. (Carlsbad, 
CA).  Trypsin/EDTA, DMEM, and FBS, human foreskin fibroblasts (hFF-1) were 
procured from ATCC (Manassas, VA).  MMP-2/MMP-9 substrate I, fluorogenic was 
procured from Millipore (Billerica, MA).  TG (EC 2.3.2.13) was procured from 
Ajinomoto (Fort Lee, NJ). 
 
3.2.2. DOX-loaded PLGA Nanoparticle preparations. 
DOX containing PLGA nanoparticles were prepared using double emulsion technique 
(Davda and Labhasetwar, 2002, Murakami et al., 1999).  In brief, 30% (wt/v) PLGA was 
dissolved in chloroform and 2% (wt/v) PVA solution was prepared in water containing 
0.2% (v/v) chloroform.  A 10% DOX solution was prepared and added to the PLGA 
solution in two portions, vortexing for 1 minute after each addition.  The primary 
emulsion was then added in two portions to the 2% PVA solution with intermittent 
vortexing, forming the water-in-oil-in-water (w/o/w) emulsion.  The particles 
spontaneously formed with the addition of the PLGA solution to the aqueous 2% PVA 
solution; emulsion droplets formed and chloroform diffused out from the droplets.  The 
emulsion was sonicated for 5 min using the Sonic Dismembrator Model 500 (Fisher 
Scientific).  The w/o/w emulsion was then stirred overnight to allow for the evaporation 
of chloroform, allowing the droplets to solidify and form the particles.  After evaporation, 




Supernatant was removed and particles were washed with deionized water.  Contents 
from all centrifuge tubes were then collected and sonicated for 1 minute.  This process 
was repeated once more to ensure that no DOX was left in the solution.   
Particles in solution were lyophilized i) to measure the size of formed nanoparticles using 
dynamic light scattering (Zeta PALS, Brookhaven Instruments Corporation) and ii) to 
visualize using scanning electron microscope (Joel JOEL 6360USA Inc., Peabody, MA), 
similar to a previous publication (Hong and Madihally, 2010).  In brief, freeze dried 
samples were attached to a stub using a double sided conductive tape and sputter-coated 
with gold for 1 min.  Digital micrographs were collected from random locations at 15kV 
accelerating voltage. 
 
3.2.3. Hydrogel formulation. 
Solution of 2% (wt/v) chitosan, 4% (wt/v) gelatin, 2% (wt/v) powdered low glucose 
DMEM, and 0.003% (wt/v) TG, were prepared in 0.1N HCl (Iyer et al., 2012).  The 
solution was stirred for a minimum of four hours at a temperature of 50°C.  After the 
polymers completely dissolved, 9 mL were transferred to a 50 mL centrifuge tube, placed 
in an ice bath, and four mL of 0.56 g/mL 2GP was added drop wise under constant 
stirring.  When Dox was added, DOX-PLGA nanoparticle solution was added to the 
hydrogel solution and mixed thoroughly for samples with DOX.   
 
3.2.4. Mechanical Characterization.  
Confined compression testing was performed on hydrogels using an INSTRON 5542 




Madihally, 2014).  In brief, hydrogels were prepared in 6-well tissue culture plates by 
incubating 3 mL of solution for 2 hours at 37oC.  Hydrogels were compressed at 1 mm/min 
crosshead speed at room temperature.  Data were exported to MS Excel and compressive 
modulus was calculated from the slope of the linear portion (20% to 40% strain range) of 
the stress-strain plot. 
Tensile tests were also conducted by applying the load orthogonal to compression testing 
to ensure uniform cross-linking of the hydrogels, as described previously (Ratakonda et 
al., 2012).  In brief, 20 mL of hydrogel solution was prepared in a 35mm petri dish and 
incubated for 2 hours.  After incubation, 10mm × 14 mm × 3 mm rectangular slices were 
cut out and loaded to the Instron 5542 and pulled to break at a crosshead speed of 1 
mm/min at room temperature.  After data collection, stress vs strain was plotted and the 
slope of the linear region, the elastic modulus, was determined.  For all tests, a minimum 
of three experiments were performed per condition from different preparations. 
 
3.2.5. Doxycycline release from the hydrogels. 
Acellular hydrogels were prepared following methods described in Section 2.3 with and 
without DOX and TG.  CG hydrogel prepared without DOX served as the control group.  
After a 2h incubation period, 2 mL of PBS was added on top of the hydrogel and 
incubated for 5 days.  Every 12 hours, 1 mL of PBS was collected.  DOX content was 
determined using a calibration plot constructed by varying concentrations of DOX 
solutions (0-24 mg/L) prepared in distilled water.  The absorbance of each sample was 
measured in a spectrophotometer at 375 nm, as published by others (Ramesh et al., 2011).  




concentration, which was used to determine unknown DOX concentration.  
In order to determine kd values, DOX concentration was measured by incubating DOX 
directly in PBS various times until 48 hr.  Then a first order decay rate (Costa and Sousa 
Lobo, 2001) given by  
DoxdDox Ckdt
dC        (1) 
was used to determine the decay constant kd [h-1] where CDOX [µg/mL] is the DOX 
concentration at any time t.  This equation was integrated using the limits of integration 






      (2) 
Obtained concentration values were then plotted as a ratio against corresponding time 
according to the equation.  By fitting an exponential decay function, slope value 
corresponded to the decay constant.  In order to determine the DOX release rate K 
[µg/mL.h] from the hydrogel, a single compartment was assumed.  Writing the mass 
balance gave  
DoxdDox CkKdt
dC       (3) 
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using which K value at different times were estimated from each experiment.  Obtained 
K values were multiplied by the respective time to get the total concentration released 
from the hydrogel.  For each time point, percentage release was calculated knowing the 
concentration loaded in the hydrogel (each hydrogel was loaded with DOX at a 
concentration of 50mg/L).  Obtained values were plotted to determine the release 
profiles.  To assess whether the presence of DOX nanoparticles affected the mechanical 
properties, hydrogels with DOX were submitted to the mechanical tests outlined in 
section 2.4.  To further characterize the mechanical properties of the hydrogels while 
release of DOX is under way, hydrogels were submerged in PBS and underwent 
compressive tests at 1, 3 5 and 7 days after initial submersion in PBS.  Obtained values 
were normalized to day zero values in order to understand the stability of the hydrogel in 
the absence of cells at conditions mimicking cell culture experiments. 
 
3.2.6. Cell culturing in hydrogel. 
Human foreskin fibroblasts (hFF-1) were expanded in DMEM supplemented with 15% 
FBS, following vendors protocol.  Cells were maintained at 37°C, 5% CO2/95% air, and 
fed with fresh medium every 2-3 days.  Once confluent, cells were detached with 
trypsin/EDTA and then trypsin neutralization solution was added.  Cells were centrifuged 
at 270×g for 5 min and dispersed in growth medium.  Viable cells were counted using 
Trypan blue dye exclusion assay. 
hFF-1 between the passages 3-10 were stained with CFDA-SE, and seeded onto hydrogel 
samples using the procedure previously developed by our group with minor 




with and without DOX nanoparticles, and CG with TG (CG-TG) hydrogel with and 
without DOX nanoparticles.  In brief, cells were incubated in growth medium containing 
2 µM CFDA-SE at 37°C for 20 min followed by washing the excess stain with growth 
medium.  Then, 0.5×106 cells/mL hydrogel were mixed uniformly.  One milliliter of 
mixture was dispensed into the 6-well plate and incubated at 37C for 2 hours to allow 
for gelation.  Then, growth medium was added.  After 24 hours, the growth medium was 
replaced with fresh medium.  This process was repeated every 48 hours until day 5.  The 
spent medium collected was used for viability and MMP-2/MMP-9 analyses. 
After five days, cytoplasmic CFDA-SE content was extracted from live cells by three 
cycles of freeze and thaw, using the procedure previously reported (Iyer et al., 2012).  In 
brief, cell culture medium was replaced with 2mL PBS and placed at -20°C until the PBS 
froze.  After the PBS froze, the plates were thawed at room temperature and the cycle 
was repeated.  Then, the solution was collected and the absorbance was determined using 
a spectrophotometer Gemini XS spectrofluorometer (MDS technologies, Santa Clara, 
CA) at the excitation and emission wavelengths of 485 nm and 525 nm, respectively.  
The CFDA-SE content in the spent medium was also assessed.  Obtained fluorescence 
intensities were converted to number of cells creating a calibration of fluorescence 
intensity to number of cells obtained as previously described (Iyer et al., 2012), with 
minor modifications.  In brief, cells pre-stained with CFD-SE were seeded at 0.25, 0.40 
and 0.50 million/mL CG-TG-DOX solution.  Upon gelation, CFD-SE content was 
extracted by a freeze-thaw cycle similar to that explained above.  Hydrogels without cells 
were used as blanks.  A calibration plot was obtained between fluorescence and the 




Some samples were processed for histology analysis.  Samples were fixed using 3.7% 
formaldehyde for 30 min at room temperature, washed thrice with PBS, stored in ethanol 
overnight at 4°C, sectioned and stained for Hematoxylin and Eosin (H/E).  Digital 
photomicrographs were captured at representative locations using an inverted 
microscope.   
3.2.7. MMP-2/MMP-9 activity. 
In order to understand the effect of DOX on MMP-2/MMP-9 inhibition, the amount of 
MMP-2/MMP-9 secreted into the growth medium was determined using a fluorogenic 
substrate (DNP-Pro-Leu-Gly- Met-Trp-Ser-Srg-OH) specific for MMP-2/MMP-9, using 
protocol described previously (Iyer et al., 2012, Waas et al., 2002).  In brief, the 
absorbance of MMP-2/MMP-9 was recorded at 280 nm excitation wavelength and 360 
nm emission wavelength.  A 200 µL solution of sampled media and MMP-2/MMP-9 
(1mM solution in DMSO) was prepared in a 1:1 ratio.  After twenty minutes, the samples 
were analyzed using a spectrophotometer.  The amount of fluorescence was normalized 
using the total protein content of the samples, measured using a commercially available 
bicinconic acid assay from Pierce Chemical Company.   
 
3.2.8. Statistical evaluation. 
All experiments were repeated three or more times.  Significant differences between two 
groups were evaluated using a one-way analysis of variance (ANOVA) with 95% 






3.3. Results and Discussion 
3.3.1. Characterization of DOX-loaded 
PLGA nanoparticles. 
First, forming DOX-containing particles was 
evaluated either using PLGA or chitosan.  
Based on ease of synthesis and uniform shape 
when observed under a scanning electron 
microscope, formed PLGA nanoparticles via 
double emulsion technique were selected for 
further use.  However, SEM analysis (Figure 
3.1a) indicated a broad size distribution of 
PLGA nanoparticles.  In order to reduce the 
size distribution, particles were passed through two syringe filters containing 0.45m and 
0.22m pore diameters.  A fraction passed through a 0.22m filter and were collected 
and characterized using a dynamic light scattering.  These results showed that the PLGA 
nanoparticles were 260(12) nm in size.  Incorporating DOX to the nanoparticles 
increased the overall size to 367(20).  These particles were used in subsequent 
experiments.  It is believed that after nano particles were passed through filter the 
majority of the nanoparticles aggregated to form larger particles than the filter pore size. 
This aggregation could have been caused during centrifugation or freeze-drying of 
samples for characterization using a dynamic light scattering. 
 
  Figure 3.1.  Nanoparticles and 
hydrogel stability.  (a) Micrograph of 
DOX-loaded PLGA nanoparticles.  
(b) Photograph showing the effect of 
incubating with the medium on the 




3.3.2. Effect of TG crosslinking on hydrogel strength. 
Previously, we have shown that presence of gelatin in substrates increases gelatinase 
activity (Iyer et al., 2012).  Those experiments were performed using 0.5 % (wt/v) 
chitosan and 0.5 %(wt/v) gelatin solutions.  During preliminary cell experiments (data not 
shown) using nine times more cells per mL of hydrogel than the previous study (Iyer et 
al., 2012), hydrogels were found to be unstable.  This is attributed to the increased 
gelatinase and other proteolytic activity due to increased cell number, as this instability 
was not noticed with reduced cell number even after ten days of culture (Iyer et al., 
2012).  The concentration of the hydrogel solution was increased to 2 % (wt/v) chitosan 
and 4 %(wt/v) gelatin to address the stability issue.  Increased concentrations of chitosan 
and gelatin still showed temperature sensitive hydrogel formation.  However, any further 
increase in chitosan along with gelatin caused premature gelation.  Hence, TG was added 
to the hydrogel to increase the hydrogel stability further.   
In order to test the effect of these formulation changes, cells were added to the hydrogel 
and cultured for five days.  All formulations gelled at 37C i.e., changes in the 
formulation did not affect gelation characteristics.  At the end of the experiment, they 
were exposed to Trypsin/EDTA solution (Figure 3.1b).  The only hydrogel sample that 
was stable at the end of the experiment was the hydrogel containing TG.   
 
3.3.3. Effect of DOX and TG on the stability of the hydrogels. 
During cell culture experiments, it was noted that CG hydrogels experienced some 
instability, especially during the first 2-3 days.  On the other hand, there was no 




mean that the gelatin crosslinking is completed by within 2-3 days.  To determine 
whether the addition of DOX nanoparticles altered the mechanical properties, the 
compressive modulus was obtained for hydrogels containing DOX nanoparticles at 33 µL 
of nanoparticles/L of hydrogel solution.  First, values at day zero i.e., without incubation 
in PBS were evaluated.  To measure the effect of crosslinking on mechanical properties, 
compressive modulus was obtained from the linear region of stress -strain plot (Figure 
3.2a).  Since the hydrogels were kept at 37C, TG cross-linking reaction occurred at that 
temperature which is known to be favorable (Bode et al., 2011).  The compressive 
modulus of 2 % (w/v) chitosan and 4% (w/v) gelatin hydrogel was 5.8 (1.56) kPa 
 Figure 3.2.  Influence of adding DOX Influence of TG crosslinking on the hydrogels.  
(a) Stress-strain response between the TG with medium added to the CG.  (b) 
Compressive moduli on day zero.  Asterisk indicates p < 0.05 between the groups 
indicated. (c) Tensile properties showing the isotropic cross-linking.  (d)  Changes in 




(Figure 3.2b).  Addition of DOX-containing PLGA nanoparticles to CG moderately 
increased the modulus to 7.7 (1.21) kPa.  However, addition of TG to CG without 
DOX-containing PLGA nanoparticles increased the compressive modulus to 19.3 (1.41) 
kPa.  This increase is probably due to the addition of growth medium rather than TG, as 
the cross-linking reaction takes days rather than minutes.  A similar increase was noticed 
in CG-TG samples with DOX-containing PLGA nanoparticles.  The modulus marginally 
reduced to 17.1 (2.21) kPa.  
To ensure that crosslinking was uniform throughout the hydrogel, tensile tests were 
conducted by stretching the CG hydrogels with TG in the orthogonal direction to that 
used in compression.  Elastic modulus was nearly identical to the compressive modulus, 
suggesting that the hydrogels are isotropic (Figure 3.2c) and TG cross-linking is uniform, 
as expected due to mixing of TG in the solution prior to gelation.  Minor differences 
between elastic and compressive modulus could be attributed to the differences in 
experimental setup.  Compressive tests were performed in a confined condition while 
tensile tests were unconfined.  Water resistance could add to stiffness in compression, 
whereas in tensile tests, any water excreted would not add resistance.  
In order to understand the stability of the hydrogels better, samples retrieved after 
incubation in PBS at 37C were measured by confined compression tests.  At day 1 
(Figure 3.2d), all samples experienced a reduction in compressive modulus, which could 
be due to removal of 2GP from the hydrogels.  Hydrogels containing growth medium 
experienced more of a reduction in the mechanical properties at day 1. This could be due 
to growth medium leaching out into PBS and thus weakening the hydrogel. After day 1, 




However, it is unclear why the addition of DOX nanoparticles helps increase the 
compressive modulus over time.  It is possible that there is some interaction between 
PLGA and chitosan, and thus increasing its mechanical strength {Chronopoulou, 2013 
#552;Schexnailder, 2009 #551;Wang, 2013 #553}. At day 7, the hydrogel containing 
both TG and DOX nanoparticles was the only sample that showed an increase in 
compressive modulus.  It is evident that the crosslinking of TG starts 24 hours after 
incubation.   
 
3.3.4. Release profile of DOX in hydrogel embedded with nanoparticles 
In order to determine the optimal conditions for DOX release, DOX-containing 
nanoparticles were dispersed into the CG hydrogel (with and without media and TG) 
solution and subsequently placed into PBS (pH=7.4) solution.  From samples where 
DOX nanoparticles were directly added to the PBS solution, the decay constant was 
obtained (Figure 3.3a) by fitting the exponential function, following Equation (2).  Then 
the kd value was found to be 0.0191 h-1.  Then, using
dk
Lnt 22/1  , the half-life of DOX was 
calculated which corresponded to 36.3 h.  This is somewhat higher than reported in serum 
(Agwuh and MacGowan, 2006).  Others have shown similar profile in PBS, and could be 




Using the calculated kd values in Equation (4), actual release rate, K, from the hydrogels 
were assessed.  Evaluation of release kinetics showed that much of the DOX release 
occurred within the first 24h in CG hydrogels (Figure 3.3b).  Cross-linking CG with TG 
prolonged the release profile significantly, and nearly 90% of the delivery occurred by 
96h.  CG hydrogels without DOX were used as controls, which showed no DOX during 
the study period.  Those nanoparticles, which completely encapsulated the DOX could 
prolong the release of DOX to long term.  Further experiments are necessary to 
understand this scenario.  
 
3.3.5. Influence of DOX and TG on hFF-1 colonization. 
In order for CG hydrogel with TG and DOX to be used as a cell carrier, it must support 
cell culture.  To assess the hydrogel’s ability to support cell culture, CFDA-SE stained 
hFF-1s was distributed in the solution and cultured for five days; CFDA-SE is non-toxic 
and used in vivo for visualizing cells or studying uptake of labeled substrates.  First, the 
collected medium was assessed for CFDA-SE fluorescence intensity and the number of 
 Figure 3.3.  DOX release characteristics.  (a) Stability of DOX in PBS.  Insert is a 
calibration plot of DOX concentration to absorbance.  (b) Percentage of DOX released 
from the hydrogel.  CG-No DOX are actual numbers as they cannot be normalized to 
the initial concentration.  Each data point is an average of 3 samples and error bars 




dead cells.  The highest number of cells (Figure 3.4a) were recovered from the CG-TG 
with DOX nanoparticles.  Since there were no significant differences between CG with 
and without DOX nanoparticles, higher cell death in CG-TG with DOX may not be due 
to DOX alone.  In addition, others have shown that used range of TG concentration is not 
toxic to cells (Broderick et al., 2005).  After five days, cells remaining in the hydrogel 
were analyzed.  Contrary to high cell death, 60% of cells (Figure 3.4b) originally seeded 
in the hydrogel were recovered in the CG-TG hydrogels with DOX nanoparticles.  
However, only 40-43% cells were recovered from other formulations.  DOX helps with 
cell adhesion and retention (Franco et al., 2006) and cells retrieved from CG with DOX 
were moderately higher than CG alone, although there was no statistical significance.  




wound healing.  They secrete MMPs more than other cell types.  The improved 
mechanical property of the hydrogel with TG and reduced MMP activity by DOX could 
be the reason for seeing the improved cell survival in CG-TG and DOX.  Other cell types 
have to be tested to understand whether TG cross-linking alone is sufficient to improve 
viability. The cumulative number of cells i.e., cells in the medium and in the hydrogel 
were 100% in CG-TG hydrogels with DOX nanoparticles.  In other conditions, we could 
not account for nearly 25-32% of the cells that were initially seeded.  The highest number 
of cell loss was in CG hydrogels, similar to in vivo results where cell attrition is 
observed.  Since the number of cells were mixed together, counted, and divided into four 
equal parts (one for each condition), alterations in initial seeding could not lead to such 
variation.  Alternatively, when the medium is changed, some floating pieces of hydrogels 
 Figure 3.4. Effect on cell retention and survival.  (a) Number of dead cells determined 
indirectly using the amount of CFDA-SE present in the spent medium on days 1, 3 
and 5.  Asterisk indicates p < 0.05 between CG-TG-Dox and CG hydrogels (b) 
CFDA-SE intensity from the cells were retrieved from the hydrogel on day 5.  
Asterisk indicates p < 0.05 between CG-TG-Dox with other conditions (c) Confocal 
fluorescent micrographs stained for CFDA-SE. (d and e) H/E stained micrograph 




and cells are collected.  We chose to label the intact cells in those components as dead 
cells (even though they were still viable), as they will be lost in the in vivo scenario.  In 
any case, cross-linking CG with TG and adding DOX nanoparticles significantly 
improved the retention of cells.  Nevertheless, we measured the total fluorescence of 
CFDA-SE that is initially present in the cells.  CFDA-SE is a cytoplasmic stain and 
equally inherited by the daughter cells during cell division.  However, when we quantify 
CFDA-SE content by spectrophotometry, the total amount of CFDA-SE does not change, 
due to CFDA being equally divided into daughter cells, compared to initial cytoplasmic 
content.  Hence, cell proliferation could not be tested due to the fixed fluorochrome 
content during cell culture.  We need to do flow cytometry to determine cell growth, 
similar to our previous studies (Iyer et al., 2012).  Despite significant improvement in 
viable cells, nearly 40% of the cells were dead cells.  Hence, one has to further optimize 
the hydrogel for cell survival by including addition of oxygen releasing molecules and 
evaluation of the stability of growth medium components.  
In order to understand the in situ distribution and viability of cells, hydrogels were 
assessed by confocal fluorescent microscope.  These results showed (Figure 3.4c) 
uniform distribution of hFF-1 within the hydrogel.  However, cross-linking may decrease 
the diffusion of nutrients and metabolic products, creating nutrient inefficiency and 
reduced viability.  In order to determine the changes in morphology of the hydrogel, H/E 
sections were analyzed.  These results showed that CG-TG without DOX Nanoparticles 
(Figure 3.4d) appeared less dense compared to CG-TG with DOX nanoparticles (Figure 
3.4e).  This could be an indication of a more crosslinked and stable hydrogel structure.  




analyses are necessary to better understand the impact of these changes and the need for 
additional growth medium components.  
 
3.3.6. MMP-2/MMP-9 activity 
First, accumulated total protein content in the spent medium was analyzed using 
bicinchoninic acid (BCA) assay to understand the effect of modifications in the hydrogel.  
These results (Figure 3.5) showed a higher total protein content TCP relative to CG 
hydrogels on day 1.  Trends in total protein contents during the study period were similar 
in CG and CG-TG hydrogels with DOX.  Hydrogel cultures in general had a lower 
amount of total proteins relative to TCP, probably due to the entrapment of secreted 
proteins within the hydrogel.  In any case, hydrogels without DOX had a higher level of 
 Figure 3.5.  MMP secretion into the medium.  (a) Total protein content in the spent 
medium.  (b) MMP-2/MMP-9 secreted into the medium.  Each data point is an 
average of at least four pooled samples and error bars correspond to standard 





total protein content relative to hydrogels with DOX cultures in contrast to the number of 
cells retrieved on day 5.  Previously, we have shown the gelatin is stable in these 
hydrogels and alterations are not due to increased gelatin leaching (Iyer et al., 2012).  
Gelatinases are present for a considerable amount of time during the wound repair 
process (Ravanti et al., 1999).  DOX is an inhibitor of MMP2/MMP9 or pro-MMP 
activation by interacting with the zinc or calcium atoms within their structural center 
required for stability.  Further, TG cross-linked collagen is degraded slowly by MMPs 
(DM et al., 2006).  In order to understand the implication of delivery of DOX and TG 
cross-linking, MMP2/MMP9 activities were measured.  On day 1, there was a significant 
effect of DOX in TCP cultures (Figure 3.5), but not at other time points, probably due to 
shorter half-life of DOX in the medium.  On the contrary, DOX had some effect in CG 
scaffolds with and without TG on day 3.  There was a significant reduction in MMP-
2/MMP-9 activity CG-TG hydrogels with DOX on Day 3 relative to day 1.  Although 
part of this reduction could be due to the increased protein content, similar to CG 
hydrogels, the slope of reduction was attributed to the DOX release.  Despite further 
increase in total protein content on day 5, moderate increase in MMP-2/MMP-9 activity 
was observed.  This could probably be due to an increased amount of nutrients in the 
hydrogels, which increased the activity of cells in remodeling the activity.  On day 5, 
however, CG hydrogels alone had increased MMP-2/MMP-9 activity, while addition of 
TG had suppressed MMP-2/MMP-9 activity.  This could be related to the stability of the 
CG hydrogels which may lead to burst release of DOX and then follow the same path as 
TCP samples.  This suggests that DOX delivery through the hydrogel is beneficial in 






This study demonstrated the possibility of preparing CG injectable hydrogels that can be 
used to deliver cells. DOX loaded PLGA nanoparticles were then placed in different 
hydrogels. The release profile analyzed by a single compartment modeling showed that 
DOX can be released in a controlled manner using CG cross-linked with TG. Addition of 
TG and media improved the mechanical property of the hydrogels with and without 
fibroblasts. CG cross-linked with TG showed significant improvement in the retention of 
human foreskin fibroblasts (hFF-1) cultures at day 5; cells recovered from CG-TG was 
2.5 times more than that collected from CG with DOX release. There was inhibition of 
MMP-2/MMP-9 activity, directly correlating cause and effect of DOX release levels and 
improvement in hydrogel stability, which further helped cell retention. Cell cultures 
showed no toxicity from DOX at the proposed concentration, although TG crosslinking 
had some effect on cytotoxicity. Improved retention of cells holds promise in using the 







IMPROVED CHITOSAN-GELATIN INJECTABLE HYDROGELS FOR ADULT 
STEM CELL DELIVERY FOR CARDIAC REPAIR 
4.1 Introduction 
Regeneration of cardiac tissue was investigated by delivering stem cells to damaged 
cardiac tissue caused by myocardial infarction (Segers and Lee, 2008, Ye et al., 2011).  
However, 90% of injected cells were dead after one week due to various factors including 
delivery method and microenvironment of injected cells.  Cell death can be attributed to a 
lack of uniform distribution and a lack of nutrients and oxygen due to the absence of 
blood flow to the tissue (Kurdi et al., 2010). To address these problems, biomaterials such 
as hydrogels and scaffold can be applied to cell based therapies (Kurdi et al., 2010, 
Pascual-Gil et al., 2015).  To prevent cells from being lumped and delivered into a small 
area in the heart, hydrogels or scaffold can be first seeded with the cells and then 
implanted in the heart.  With this method, cells will be distributed among the scaffold or 
hydrogel and be able to treat a larger area.  In addition, both hydrogels and scaffolds can 
be designed to contain nutrients and oxygen releasing particles to supply the embedded 
cells with nutrients and oxygen (Camci-Unal et al., 2013, Oh et al., 2009).  The 




With the use of scaffolds one must conduct an open heart surgery to implant the scaffold 
to the affected region. However, if one uses a hydrogel, a major complicated surgery 
approach can be avoided. Hydrogels can be design to respond to environmental changes 
such as temperature change, and therefore, are an excellent candidate for a non-invasive 
approach (Chenite et al., 2000). Researchers have shown that short term in vivo rat bone 
marrow derived stem cell survival was increased to 23% at the end of one week with the 
addition of a type I collagen gel (Simpson et al., 2007). Cell death is still being attributed 
to lack of nutrients and lack of oxygen. The addition of biomaterials have also brought a 
new set of problems, including mechanical stability, gelation time, and mechanical 
property compatibility (Li and Guan, 2011, Ye et al., 2011). Chitosan hydrogels are 
increasingly being explored to serve as cell carriers for biomedical approaches. This is in 
part due to their quick thermoresponsive characteristic that allows them to be a liquid at 
room temperature and solidify at body temperature (Cheng et al., 2010, Chenite et al., 
2001, Chenite et al., 2000). Chitosan is obtained by deacetylation of chitin, the second 
most abundant polymer occurring in nature (Shigemasa Y, 1994).  Chitosan is 
metabolized into non-toxic D-glucosamines by lysozymes (Mi et al., 2002, Tomihata and 
Ikada, 1997) and hence is biodegradable.  In addition to being degradable and easily 
available, chitosan also shares features similar to glycosaminoglycans present in the 
extracellular matrix. Chitosan hydrogels can be developed to have a wide range of elastic 
moduli by simply changing the concentration of chitosan (Cheng et al., 2010, Huang et 
al., 2006, Mi et al., 2002, Ngoenkam et al., 2010). Chitosan hydrogels have previously 
been used to regenerate cardiac tissue with limited success during in vivo experiments 




stability of the hydrogel. As previously mentioned, chitosan is biodegradable and the 
environment surrounding damaged cardiac tissue is populated with extra cellular matrix 
degrading enzymes. A disadvantage of using chitosan only hydrogels is that chitosan has 
no sites for cells to attach. Therefore, a polymer containing binding site is usually 
combined. In our laboratory, we have previously used gelatin to compliment chitosan 
hydrogels to be more compatible with cells (Huang et al., 2005, Iyer et al., 2012). 
Hydrogels containing gelatin are subject to premature degradation caused by an increased 
activity of matrix metalloproteases, specifically MMP-2 and MMP-9 (Makowski and 
Ramsby, 1998).  However, we have previously shown how to increase the stability of the 
hydrogel by the addition of PLGA nanoparticles encapsulating doxycycline hyclate 
(Tormos et al., 2015).  
Previously, we developed a chitosan-gelatin hydrogel that were able to withstand hFF-1 
culture for 1 week (Tormos et al., 2015).  In addition, this hydrogel had mechanical 
properties that were in the same order as cardiac tissue (Tormos et al., 2015).  We were 
able to increase the mechanical stability of the hydrogel using a two prong strategy 
(Tormos et al., 2015). First, inhibition of MMP-2 and MMP-9 activity was achieved by 
exposing cells to doxycycline hyclate (Tormos et al., 2015). Second, the hydrogel’s 
gelatin molecules were crosslinked by using transglutaminase. These two approaches 
helped increase the stability of the hydrogel both short and long term. In this study, we 
investigated the effect that different commercially available chitosan and gelatin had on 
the hydrogel’s mechanical properties. Since improvements still felt short of our goal of 
obtaining a hydrogel with mechanical properties similar to cardiac tissue, we varied the 




optimal conditions to cyclical testing and relax and hold tests to assess the hydrogel’s 
ability to withstand continuous contraction and expansion. Finally, we investigated the 
hydrogel’s ability to support human adipocyte stem cell culture for up to 3 weeks and 
assessed whether similar mechanical properties and a 3D environment were enough to 
differentiate human adipocyte stem cells to cardiomyocytes.  
 
4.2 Materials and methods 
4.2.1. Sources for Materials. 
Low MW chitosan (50 kDa and 75-85% deacetylation), medium (190 - 310 kDa and 75-
85% deacetylation), high molecular weight chitosan (310 - 375 kDa and 75-85% 
deacetylation), gelatin type A (100, 175, and 300 Bloom) and type B (225 Bloom), β-
glycerophosphate (2GP), 50:50 poly lactic-co-glycolic acid (PLGA, 110 kDa), polyvinyl 
alcohol (PVA, 30-70 kDa, 87-90% hydrolyzed), Doxycycline hyclate (DOX, 
pharmaceutical secondary standard) and bovine serum albumin (BSA) were procured 
from Sigma Aldrich Co (St. Louis, MO).  Phosphate buffer solution (PBS, pH=7.4), 5-
(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE) - mixed isomers, 
StemPro® Human Adipose-Derived Stem Cells, MesenPRO RS™ Medium kit, L-
glutamine (200 mM, liquid), and powdered DMEM low glucose were procured from Life 
Technologies. (Carlsbad, CA).  MMP-2/MMP-9 substrate I, fluorogenic was procured 
from Millipore (Billerica, MA).  Food grade Active TI transglutaminase (Enzyme 
Commission 2.3.2.13) was procured from Ajinomoto (Fort Lee, NJ).  Trypsin-EDTA was 
purchased from American Type Culture Collection (ATCC – Manassas, VA).  Fresh 




OK.  Anti-GATA4 antibody (catalog no. ab84593) was purchased from Abcam 
(Cambridge, MA).  Purified anti-human CD105 (catalog no. 323202), FITC Donkey anti-
rabbit IgG (catalog no. 406403), and PE anti-mouse IgG1 (catalog no. 406607) was 
obtained from Biolegend (San Diego, CA).  DAPI Nucleic Stain (catalog no. D1306) was 
purchased from Thermo Scientific Pierce (Waltham, MA).  5-azacytidine (catalog no. 
A1287) and Dulbecco’s Modified Eagle’s Medium – low glucose (catalog no. D6046) 
was purchased from Sigma Aldrich (St. Louis, MO).  Cultrex® Mouse Laminin I (1 
mg/mL) catalog no. 3400-010-01 was purchased from Trevigen (Gaithersburg, MD).  
Fetal Bovine Serum (catalog no. 30-2020) was purchased from ATCC (Manassas, VA). 
 
4.2.2.  Hydrogel formulation. 
Hydrogel solution was created by previous methods with minor modification (Tormos et 
al., 2015).  In brief, chitosan, gelatin, powdered low glucose DMEM (cat no. 31600-083), 
and TG, were prepared in 0.1N HCl according to previous reported methods(Tormos et 
al., 2015).  Solutions were stirred for a minimum of four hours at a temperature of 50-
70°C.  After the polymers completely dissolved, solution was transferred to a 50 mL 
centrifuge tube, placed in an ice bath, and 0.56 g/mL 2GP was added drop wise under 
constant stirring until pH reached biological conditions (7.2-7.4).  When Dox was added, 
DOX-PLGA nanoparticle were filtered through a 0.22µm filter and then added to the 
hydrogel solution and mixed thoroughly.   
 
4.2.3.  Mechanical Characterization.  




INSTRON 5542 (INSTRON, Canton, MA) and a custom-built anvil with a diameter of 
25mm, as described previously (Tormos et al., 2015).  In brief, hydrogels were casted in 
6-well tissue culture plates by incubating 3 mL of solution for 2 hours at 37oC.  Hydrogels 
were compressed at 1 mm/min crosshead speed.  Data were exported to MS Excel and 
compressive modulus was calculated from the slope of the linear portion (20% to 40% 
strain range) of the stress-strain plot. 
Tensile tests.  Tensile tests were also conducted by applying the load orthogonal to 
compression testing to ensure uniform cross-linking of the hydrogels, as described 
previously (Tormos et al., 2015).  In brief, 20 mL of hydrogel solution was prepared in a 
35mm petri dish and incubated for 2 hours.  After incubation, 10mm × 14 mm × 3 mm 
rectangular slices were cut out and loaded to the Instron 5542 and pulled to break at a 
crosshead speed of 1 mm/min at room temperature. After data collection, stress vs strain 
was plotted and the slope of the linear region, the elastic modulus, was determined.  For 
all tests, a minimum of three experiments were performed per condition from different 
preparations.   
Stress relaxation experiments.  Hydrogel samples were prepared similar to tensile tests 
were used in these experiments and porcine heart tissue samples were prepared as 
described in section 2.1.  These samples were subjected to seven successive steps of ramp 
and hold tests.  Each ramp was stretching to 5% at 2.5%/s of the original length.  Each 
holding was for 20 seconds.  Stress was plotted against time.  To understand the effect of 
each stage on the hydrogel, they were normalized by subtracting stress and time elapsed 
at the beginning of each stage.  In addition, reduced relaxation function was calculated to 




(Ratakonda et al., 2012).  Porcine hearts were sliced while frozen at a thickness of 3mm 
using a deli slicer blade.   
Cyclical tests. Hydrogel samples were prepared similar to tensile tests and porcine heart 
tissue samples were prepared as described in section 2.1 were stretched 10% of their 
length and then returned to their original position.  Sample were stretched at a speed of 
72 cycles per minute for up to 30 min.   
 
4.2.5. Cell culturing in hydrogel. 
Human adipocyte stem cells (hASCs) were expanded in MesenPRO RS™ Medium kit, 
following vendor’s protocol.  Cells were maintained at 37°C, 5% CO2/95% air, and fed 
with fresh medium every 2-3 days.  Once confluent, cells were detached with trypsin-
EDTA 1X and then trypsin was neutralized using MesenPRO RS™ Medium.  Cells were 
centrifuged at 210×g for 5 min and dispersed in growth medium.  Viable cells were 
counted using Trypan blue dye exclusion assay. 
hASCs between the passages 3-8 were stained with CFDA-SE, and seeded onto hydrogel 
samples using the procedure previously developed by my laboratory with minor 
modifications (Tormos et al., 2015).  In brief, cells were incubated in growth medium 
containing 2 µM CFDA-SE at 37°C for 20 min followed by washing the excess stain with 
growth medium.  Cells were added to the hydrogel at 0.5×106 cells/mL hydrogel and 
mixed evenly within the solution.  0.5 mL of mixture was then dispensed into the 6-well 
plate and incubated at 37C for until gelation was achieved.  Then, 2mL growth medium 




analysis and replaced with fresh growth medium.  This process was repeated every 48 
hours until completion of experiment. 
After completion of experiment, cytoplasmic CFDA SE content was extracted from live 
cells by three cycles of freeze and thaw, using the procedure previously reported (Tormos 
et al., 2015).  In brief, cell culture medium was replaced with 2mL PBS and placed at -
20°C until the PBS froze.  After the PBS freezes, the plates were thawed at room 
temperature and cycle was repeated.  Then, the solution was collected and the absorbance 
was determined using a spectrophotometer Gemini XS spectrofluorometer (MDS 
technologies, Santa Clara, CA) at the excitation and emission wavelengths of 485 nm and 
525 nm, respectively.  The CFDA-SE content in the spent medium was also assessed.  
Obtained fluorescence intensities were converted to number of cells using a calibration of 
fluorescence intensity to number of cells obtained as previously described (Tormos et al., 
2015).  
 
4.2.6.  2D Differentiation protocol.  
Differentiation in 2-D culture was carried out in two different ways similar to previous 
reports (Choi et al., 2010, Wan Safwani et al., 2012, van Dijk et al., 2008, Chang et al., 
2012).  First, differentiation of hASCs was attempted using Phorbol Myristate Acetate 
(PMA). In brief, 100,000 hASCs were seeded on each well of a six-well plate. 24 hours 
after seeding, cells were washed with PBS twice and growth medium containing 10µM 
PMA was added.  Growth medium was changed every three days and the experiment 
concluded after nine days.  On day nine, cells were harvested and stained with antibodies.  




of troponin) are genetic markers commonly used to identify cardiomyocytes (Heineke et 
al., 2007, Wang et al., 2004). The second method was to use laminin and 5-azacytidine as 
others have previously done (Choi et al., 2010, van Dijk et al., 2008, Wan Safwani et al., 
2012). Briefly, for hASCs cultured on laminin, 2mL of a PBS solution containing laminin 
(concentration 0.42µg/mL) was added to each well. After 30minutes, wells were washed 
with fresh PBS. 10,000 hASCs were cultured in each well and supplemented with control 
growth medium (DMEM supplemented with 10% FBS).  After 24 hours, cells were 
washed with phosphate buffer solution (PBS) and growth medium containing 5-
azacyidine (9µM) or controlled medium was added.  Twenty-four hours after exposure to 
AZA, cells were washed with PBS and supplemented with controlled growth medium for 
the duration of the experiment. Growth medium was replaced every three days until 
completion of the experiment.  After 3 weeks culture, hASCs were washed and stained 
with Endoglin (CD 105), hASC marker, GATA4, cardiac marker, and DAPI, nucleic acid 
marker (Choi et al., 2010, van Dijk et al., 2008, Wan Safwani et al., 2012).  
 
4.2.6.  Immunohistochemistry 
After completion of cell culture experiments, some samples were processed for 
cryosectioning.  Samples were submerged in Tissue-Tek® O.C.T. Compound and frozen 
at -20°C.  Samples were sent to Stephenson Cancer Tissue Pathology Core at the 
University of Oklahoma for cryosectioning. Samples were cut at a thickness of 6µm. 
After cryosectioning, slides were prepared for immunohistochemistry. First, using a PAP 
pen a border was drawn around the sample of interest. Next sample was washed with 




crosslink any non-specific sites and incubated at room temperature for 30 minutes. After 
30 minutes, slide was rinsed with PBS and primary antibody was added and incubated for 
60 minutes at room temperature.  After 60 minutes, slide was rinsed with PBS and 
secondary antibody was added and incubated for 30 minutes at room temperature. After 
30 minutes, slide was rinsed with PBS and either DAB or DAPI was added and incubated 
at room temperature for 5 minutes.  If DAB was added, after 5 minutes, slide was rinsed 
with PBS and hematoxylin was added and incubated for 15 seconds. After 15 seconds, 
slide was rinsed thoroughly with PBS. Slide was covered with 2-3 drops of cytoseal and a 
cover slip and was allowed to dry in a dust free place.  Digital photomicrographs were 
captured at representative locations using a CCD camera connected to an inverted 
microscope.   
 
4.2.7. RNA expression 
RNA expression of CD105 and CD44 was analyzed by qPCR. Cells cultured on 6 well 
plate were harvested using trypsin. RNA was isolated using RNeasy Mini Kit from 
Qiagen and following vendor’s protocol. After RNA was isolated, RNA concentration 
was determined by using Nanodrop 1000 (Thermo Scientific).  Next, RNA was purified 
by using DNase I, Amplification Grade (cat No. 18068-015) from ThermoFisher 
Scientific. After all DNA has been digested, sample is prepared for amplification. RT-
PCR was carried out by using SuperScript™ III First-Strand Synthesis SuperMix for 
qRT-PCR (cat. No. 11752-050) from ThermoFisher Scientific and following their 
protocol. Amplification was carried out in 0.2mL centrifuge tube with a domed cap from 




programmable thermal controller (MJ Research, Inc.). Next, qPCR was achieved using 
SYBR® GreenER™ qPCR SuperMix Universal from ThermoFisher Scientific (cat No. 
11762-100) and following vendor’s protocol, with minor modifications.  Vendor’s 
protocol was modified to account for a smaller volume than recommended (20µL instead 
of 50µL). Primers’ sequence for adipocyte stem cell markers were obtained from Su et al 
(Su et al., 2014). Custom primers were ordered from Integrated DNA Technologies 
(Coralville, IA).  Primers used are presented in Table 1 along with their sequence. qPCR 
was carried out in a 96 well plate and using the 7500 Real Time PCR System (Applied 
Biosystems, Grand Island, NY).  Results from qPCR experiment were analyzed using 
7500 System Software (Applied Biosystems, Grand Island, NY). 
 
4.2.8. Statistical evaluation. 
All experiments were repeated three or more times.  Significant differences between two 
groups were evaluated using a one-way analysis of variance (ANOVA) with 95% 
confidence interval.  When P<0.05, differences were considered to be statistically 
significant. 
 
4.3 Results and discussion 
4.3.1.  Effect of Gelatin and Chitosan Properties on Compressive properties 
We used the previous formulation as the baseline, a chitosan-gelatin hydrogel (CG) with 
2%wt and 4%wt, respectively (Su et al., 2014).Using LMW chitosan and type A (acid 
solubilized gelatin) 300-bloom gelatin (CG) previously, we demonstrated that the 




properties of the hydrogel (Tormos et al., 2015).  We performed compression testing on 
gel specimens at room temperature. Assuming Hook’s law, elastic modulus was 
determined from the linear region.  Others have reported that increasing the concentration 
of chitosan also increases the rate of gelation (Cheng et al., 2010, Ngoenkam et al., 
2010).  Further, hydrogels showed spongy porosity with open pore architecture, suitable 
for the diffusion of nutrients to the entrapped cells.  Hydrogels containg only chitosan 
revealed loose, irregular and larger pore diameters wheras, the collagen only based 
hydrogels exhibited interconnected fibrous network (Wang and Stegemann, 2010, Song 
et al., 2010).  However, the hydrogel’s mechanical properties were not similar to porcine 
cardiac tissue (46.89 ± 5.63 kPa).   
Commercially, there are different types of chitosan and gelatin, therefore it is important 
to characterize and investigate different types of chitosan and gelatin to determine the 
best formulation for cardiac regeneration therapy.  To assess the effect of gelatin’s type 
(either acid solubilized or base solubilized) and bloom number (or MW), we changed the 
type of gelatin while using the low molecular weight chitosan for all the formulations.  
We determined the compressive modulus for gelatin type A 100 bloom (CG-100 type A), 
gelatin type A 175 bloom (CG-175 type A), gelatin type B 225 bloom (CG-225 type B), 
and gelatin type A 300 bloom (CG, the baseline and previously used formulation).  In 
figure 4.1a, the stress and the strain from the different samples was plotted and a line was 
fitted through, the resulting slope is the compressive modulus of the sample.  In figure 
4.1b, the hydrogel with the highest compressive modulus was CG, the baseline, with a 
compressive modulus of 6.84 ± 0.70 kPa when looking at the different types of gelatin.  




formulations but no significant difference was found between the other gelatin 
formulations.  Further, to assess the effect of chitosan’s molecular weight on the 
hydrogel’s compressive modulus, we used gelatin type A 300 bloom for all different 
chitosan molecular weights.  We determined the compressive modulus for low molecular 
weight (CG), medium molecular weight (MMW), and high molecular weight chitosan 
(HMW).  In figure 4.1b, the hydrogel with the highest compressive modulus was HMW.  
 Figure 4.1. Effect of MW of Chitosan and Gelatin on linear compressive properties.  (a) 
Stress-strain curves of various samples.  (b) Effect of chitosan molecular weight on 
compressive modulus.  (b) Changes in the compressive modulus. (c) Effect of MW of 
chitosan on compressive modulus with gelatin type A 300 bloom, TG and 2% media. 
(d)  Effect of powdered growth medium concentration with LMW chitosan, gelatin type 
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This compressive modulus 10.43 ± 0.16 kPa were as our baseline was 6.84 ± 0.70 kPa. 
Previously, we have used low molecular weight chitosan and type A 300 bloom gelatin 
with 2% (w/v) growth medium and 0.003% (w/v) transglutaminase.  Using high 
molecular weight chitosan (in the absence of media and TG) resulted in a higher 
compressive modulus than low molecular weight chitosan.  Therefore, we compared our 
previously obtained data with high molecular weight chitosan with type A 300 bloom 
gelatin, 2% (w/v) media, and 0.003% TG (w/v).  The addition of media and TG hindered 
the compressive modulus of the hydrogel (figure 4.1c).  There was a significant 
difference between the two formulations.  Our previous formulation had a compressive 
modulus of 19.27 ± 1.41 kPa and the new formulation had a compressive modulus of 
8.30 ± 0.95 kPa.  
Next, we determined the effect of powdered growth medium concentration in the 
hydrogel’s formulation (Figure 4.1d). We tested two different formulations and 
compared them with our previous results.  The hydrogel’s compressive modulus was 
higher at 2% (w/v).  Higher (4% w/v) and lower (1%w/v) concentrations resulted in 
lower compressive modulus.  
 
4.3.2.  Effect of Gelatin Concentration on Compressive properties 
So far we’ve determined the best type of gelatin, type of chitosan, and amount of growth 
medium.  However, we are still not close to the compressive modulus of cardiac tissue 
46.89 ± 5.63 kPa.  Therefore, we wanted to further manipulate the formulation in order to 
obtain a hydrogel with a higher modulus.  Similar to what we did with growth medium, 




previously shown the benefits of gelatin in terms of cell attachment and spreading.  For 
cardiac application, we want cells to be able to spread, therefore, it would be beneficial to 
have more gelatin than chitosan. In our next experiment, we varied the concentration of 
gelatin from 0% (w/v) to 10% (w/v), concentrations higher than 10% (w/v) had 
premature gelation problems (Figure 4.2a). These formulations were created with low 
molecular weight chitosan (2% w/v), growth medium (2% w/v), and TG (0.003 % w/v).  
The closest compressive modulus to that of cardiac tissue was the formulation with 8% 
w/v gelatin.  This formulation had a compressive modulus of 36.64 ± 3.64 kPa.  The next 
higher concentration (10 %w/v) had a compressive modulus of 60.72 ± 1.28 kPa. Since a 
concentration of 8% w/v is closer to cardiac tissue than 10% w/v, we decided to use 8% 
w/v gelatin for further experiments.  
Compressive tests only evaluate the properties of the material in one direction.  
Therefore, we wanted to evaluate the properties of the hydrogel in another direction. 
Next, we submitted hydrogel samples to tensile tests (Figure 2b). The Tensile modulus 
 Figure 4.2.  Effect of gelatin concentration and TG cross-linking on mechanical 
properties.  (a) Compressive properties and used the model is Modulus=6.54e0.221C 
where c is the concentration in Weight%/volume.  (b) Effect of tensile testing in the 
orthogonal direction relative to compressive property. 





































was 25.02 ± 3.74 kPa. Since the mechanical properties vary along with the direction at 
which the force is applied, this hydrogel formulation can be considered anisotropic, 
which is similar to cardiac tissue.   Since chitosan chain length could show steric 
hindrance to the cross-linking reaction of gelatin with TG, the effect of MW was tested.  
Low MW chitosan (Figure 4.2a) had higher strength than high MW chitosan in the 
presence of growth media and TG.  Tensile tests were also performed by connecting the 
hydrogels in the orthogonal direction to that of the compressive directions.  Analyzed 
properties (Figure 4.2b) were similar to that of compressive condition, suggesting 
hydrogels are isotropic and different components are uniformly distributed including the 
chemical cross-linking reaction of TG. 
 
4.3.3.  Comparison of viscoelastic behavior of the hydrogel.  
Cardiac tissue is stretched in different directions and in a cyclical fashion and behaves 
like viscoelastic materials which store and dissipate energy within the complex molecular 
structure, producing hysteresis and allowing creep and stress relaxation to occur 
(Ratakonda et al., 2012, Chen et al., 2008).  Thus, a full description of the mechanical 
analysis requires nonlinear viscoelastic behavior.  For this purpose, we performed 
experiments with new formulation and compared with porcine cardiac tissue.   Also, one 
stage is not sufficient to understand the relaxation behavior as the accumulated stress 
levels in each stage is different, hence samples were subjected to 7 stages of ramp-and 
hold experiments with load limits predetermined by the linear portion of the stress–strain 
curves obtained under tensile testing.  First, a stress vs time plot showed (Figure 4.3a) 




conditions were similar to the cardiac tissue.  The initial stress accumulated in the first cycle varied from 2.5 kPa to 4 kPa in the 
cardiac tissue.  The percentage relaxation in the first stage was 45% in the first stage which decreased to 23% in the cardiac tissue.  In 
tensile mode, the relaxation in the CG hydrogel varied from 5% to 10%.  In compressive mode relaxation varied from 7% to 15%.  
This is unlike the CG porous scaffolds prepared by freeze-drying which showed nearly 90% relaxation in successive stages. 
Interestingly, the cross-linked samples showed strain hardening characteristics similar to natural tissues including cardiac tissue; the 
more the material is stretched, the stiffer it gets.  This is unlike CG porous scaffolds which showed no effect of ramp and hold on the 
stiffness characteristics of materials.  This suggests the TG cross-linking changes the properties of the matrixes and there may be a  
 Figure 4.3. Comparison of stress-relaxation behavior between porcine pericardium and hydrogel.  (a). Effect of ramp and hold on 
stress relaxation.  (b) Reduced relaxation function for different stages in the 2%8% CG hydrogel with TG.  (c). reduced relaxation 
function for porcine pericardium. 
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post-translation modification of the matrixes by TG.  To verify this point, the stress and 
time were normalized so that each cycle can be accurately compared.  Figure 4.3b-c also 
shows that hydrogel stabilizes faster than cardiac tissue during the hold of the material, 
whereas cardiac tissue takes more time to stabilize.  
4.3.4.  Comparison of cyclical behavior of the hydrogel.   
Cardiac tissue is stretched 10% of its length repetitively in cyclical form and the injected 
matrix has to support the process until maturation of the tissue (Lee and Boughner, 1985).  
Therefore, we wanted to test whether the hydrogel can withstand repeated contraction 
and expansion just as the heart tissue experiences.  We conducted cyclical test on 2%8% 
hydrogel where we took the hydrogel and stretched and contracted it 10% of its length for 
various times at a frequency of 72 cycles per minute (Figure 4.4). We observed two 
things: the first being that after 30 minutes of continues cycles the hydrogel did not break 
and no tears were observed.  Second, we quantified the stress and strain and compared it 
to porcine cardiac tissue. Except the first cycle, the rest of the cycles were identical.  
Figure 4.4. Cyclical behavior between porcine pericardium and hydrogel.  (a) Porcine 
pericardium.  (b) 2%8%CG hydrogel with TG and medium.  Shown are the first 20 
cycles in each sample.   
Strain (mm/mm)
























Hence, only first thirty cycles are shown (Figure 1g).  These results show that hydrogels 
to be used have appropriate mechanical properties for use in cardiac tissue regeneration.  
The hydrogel is able to sustain less stress than that of cardiac tissue.   
 
4.3.5.  Retention of adipocyte stem cells.   
Apart from mechanical property similarity, an important characteristic of this hydrogel is 
cell culture compatibility. To assess the hydrogel’s ability to support stem cell culture, 
stem cells stained with CFDA-SE were seeded in the hydrogel and cultured for 1,2, or 3 
weeks. Previously we have used CFDA-SE to determine in vitro retention of fibroblast 
embedded in hydrogels (Tormos et al., 2015). The amount of retention of live cells in the 
hydrogel varied from 84.09±4.02% to 79.57±2.10%, with highest viability at 1 week and 
the lowest at 3 weeks (Figure 4.5a).
These decrease in cell viability is small and probably due to degradation of scaffold. Still, 
 Figure 4.5. hASC retention and distribution after 21 days in culture.  (a) Cells 
recovered. (b) CG-M-TG hydrogel after 7 days stained with CD105-HRP (red) 
conjugate and counterstained with hematoxylin for nucleic stain (black) at 4X 
magnification. (c) 20X magnification of insert in (b). (d) CG hydrogel after 7 days 
stained with CD105-HRP (red) conjugate and counterstained with hematoxylin for 
nucleic stain (black) at 4X magnification. (e) 20X magnification of insert in (d). 





at all time points, we have surpasses our previous cell viability percentage which was at 
60% for a seven day period (Tormos et al., 2015). In addition to viability, some hydrogel 
samples were cryosectioned and stained for H&E. This comparison of CG and TG 
hydrogels shows the benefits of crosslinking gelatin molecules with TG. As it is seen in 
Figure 5b-c, TG containing hydrogels appear to have a more interconnected network, 
whereas non TG hydrogels are less connected and more prone to degradation and 
destabilization.  
 
4.3.5.  Status of adipocyte stem cells.   
Another goal of the hydrogel was to serve as a differentiation vessel for stem cells into 
cardiomyocytes.  To test whether stem cells retain their genomic profile, qPCR, flow 
cytometry, and immunohistochemistry was conducted on cells seeded on TCP and 
hydrogel samples.  hASCs are routinely characterized by detecting CD105 (or endoglin, a 
type I integral transmembrane glycoprotein) and STRO-1 (a 75kd surface protein) 
(Zannettino et al., 2008, Pierelli et al., 2001).  To confirm whether the commercially 
purchased hASC maintained these markers in extended tissue culture, I evaluated them 
by flow cytometry.  hASCs were harvested (100,000 cells) with TrypLE proteolytic 
 Figure 4.6. Presence of hASC markers a) Histogram plot for CD105. b) Histogram 




enzyme and stained with antibodies and respective isotype controls.  The cell population 
was divided into three groups.  First group, negative control group and black line in 
Figure 4.6, contained no antibody stain.  The two other groups were stained with CD 105 
and STRO-1 separately.  After analyzing these samples using the flow cytometer, I 
obtained histogram plots for all groups (Figure 4.6).  These plots show the hASCs were 
positive for both CD105 and STRO-1.   
 
First differentiating hASCs into cardiomyocytes was investigated using PMA because the 
differentiation protocol calls for shorter duration (9 days instead of 21 days for other 
methods) of incubation.  However, no morphological changes were observed on the final 
day of experiment.  PMA was substituted by 5-azacytidine and laminin similar to 
previous reports (van Dijk et al., 2008).  To verify what 5-azacytidine and laminin were a 
viable option for cardiac differentiation, hASCs were exposed to 5-azacytidine and 
cultured on laminin coated plates.  Similar to previous reports, morphological changes 
were observed at 2 weeks (Figure 4.7).  To characterize the genetic profile qPCR and 
immunohistochemistry were conducted at the end of 3 weeks.  qPCR methods outlined 
on section 4.2.8 were followed for hASCs cultured on TCP for 21 days.  qPCR methods 




showed that there was no genotypic change for hASCs cultured on TCP for 3 week 
(Figure 4.8).  For immunohistochemistry, methods outlined on section 4.2.7 were 
followed on TCP samples that have been cultured for 21 days.  Immunohistochemistry 
images shows that hASCs markers (CD105 and CD144) are present in the absence of 5-
azacytidine and laminin.  On the contrary, presence of hASC markers decrease and 
cardiac markers start to appear when exposed to 5-azacytidine and laminin.  For some 
unknown reason, cardiac markers were visible using immunohistochemistry but not on 
qPCR.  Since these experiments were conducted on different samples, it is possible that 
samples used for qPCR did not differentiate.  This is a plausible reason since 
differentiation by 5-azacytidine is somewhat inconsistent (Wan Safwani et al., 2012). 
Furthermore, immunohistochemistry was conducted on hydrogels embedded with hASCs 
and cultured for 3 weeks.  From these results we can conclude that neither the media nor 




 Figure 4.8. Effect of laminin coating and 5-Azacytidine in 2D cultures.  Green 
fluorescence color (a-c) represents FITC tagged GATA4 antibody, red fluorescence 
color (d-f) represents PE tagged CD105 antibody. Control images show no green color 
and a lot of red (a, d). This is expected as those cells were not exposed to 5-
azacytidine nor laminin. 5-azacytidine cells showed both markers, meaning some 
differentiation is taking place but not very effectively (b, e). 5-Azacytidine and 
laminin treated cells showed a high amount of green color, meaning GATA4 
expression is high, and low red color, meaning CD105 expression is low (c, f). 
a) c) b) 




The addition of a stimulant must be included for cells to differentiate.  Previously, we 
presented an injectable hydrogel that had mechanical properties similar to cardiac, was 
able to support hASC culture for three weeks without significant cell loss, and was able 
to withstand premature enzymatic degradation. Immunological staining showed that 
mechanical properties and a 3D culture environment were not enough to differentiate 
hASCs into cardiomyocytes. Therefore, we decided to include into the hydrogel 5-
azacytidine and laminin to induce cardiac differentiation. Van Dijk et. al showed that 
hASCs cultured on laminin and exposure of 5-azacytidine for 24 hours induced 
differentiation after 3 weeks (van Dijk et al., 2008). We repeated the experiments and got 








Figure 4.9. Immunohistochemical images of CG hydrogels containing TG with or without 





In this study, I evaluated the possibility of improving the mechanical properties of an 
injectable hydrogel to be used for cardiac regeneration therapy. The optimal formulation 
for cardiac regeneration therapy by investigating the effects that different molecular 
weights of chitosan, gelatin, different types of gelatin, and growth medium concentration 
had on the hydrogel’s mechanical properties. The condition with the most significant 
effect on mechanical properties was the concentration of gelatin.  I found that the amount 
of gelatin can be altered to obtain different mechanical properties without sacrificing the 
injectable hydrogel main characteristics.  In addition to determining mechanical 
properties, we also evaluated the hydrogel in activities that the cardiac tissue experiences.  
During cycle tension test, we realized that while hydrogel and cardiac tissue have similar 
profiles, cardiac tissue remains more elastic than the injectable hydrogel.  During the 
relax and hold test, we found that another similarity that this injectable hydrogel has with 
cardiac tissue is that both hardened with increased amount of stretching.  Not only did we 
observed mechanical improvements but improvements were also observed during cell 
culture experiments.  Previously, we had a 60% cell viability after 1 week of cell culture 
and now we can surpass that even at 3 weeks.  H&E staining further supports the notion 
that TG crosslinking makes the hydrogel more stable by showing a more interconnected 
material than hydrogels without TG.  Finally, we determined that media nor mechanical 
property similarity can differentiate hASCs into cardiomyocytes.  Therefore, for future 
studies, we will look into the possibility of adding a chemical stimulant known to 







AN INJECTABLE OXYGEN RELEASING CHITOSAN-GELATIN HYDROGEL FOR 
CARDIAC TISSUE ENGINEERING 
 
5.1.  Introduction 
For years, heart disease has been the leading cause of death in the United States (Mendis 
et al., 2011, Roger et al., 2012, Writing Group et al., 2010, Go et al., 2013, Members et 
al., 2012, Kochanek et al., 2011). Myocardial infarction, otherwise known as heart attack, 
affects millions of Americans every year. For years, patients who have been diagnosed 
with experiencing a heart attack have relied on preventative treatments, meaning these 
treatments focused of reducing the risk of enduring another heart attack. Thanks to 
advances in the field of tissue engineering, there is a dim light of hope for patients with 
damaged cardiac tissue (Segers and Lee, 2008, Ye et al., 2011). Researchers are utilizing 
stem cells to repair and regenerate the cardiac tissue. Researchers have seeded millions of 
stem cells in the damaged region and have had limited success. This attrition of cells is 
believed to be due to the lack of blood supply to the damaged tissue which exposes the 
implanted cells to a nutrient and oxygen deprived environment (Kurdi et al., 2010). 
Another problem is the lack of cellular distribution, however, researchers have overcome 




The addition of biomaterials introduce a number of challenges that must be addressed if 
this therapy is to be successful. These challenges include a compatibility between cardiac 
tissue and scaffold, addition of nutrients and oxygen, and mechanical stability of the 
scaffold (Kurdi et al., 2010, Pascual-Gil et al., 2015). Previous studies from our group 
have focused on developing and optimizing an injectable hydrogel with nutrients, 
mechanical properties similar to cardiac tissue, and prolonged stability of the material 
(Tormos et al., 2015). This study will focus on delivering oxygen to cells embedded in 
the damaged tissue. Oxygen generating materials are centralized over the production of 
hydrogen peroxide because with the production of two hydrogen peroxide molecules it 
will further react to produce two molecules of water and a molecule of oxygen (Equation 
1) (Camci-Unal et al., 2013).  
2  →  + 2  
Solid inorganic peroxides, such as calcium peroxide (CaO2), magnesium peroxide 
(MgO2), and sodium percarbonate (Na2CO2), are the primary candidates for the 
production of hydrogen peroxide. This is because upon the reaction of solid inorganic 
peroxides and water, hydrogen peroxide will be formed. For instance, take calcium 
peroxide as an example (Equation 2). 
2 +  4  → 2 + 3   
However, the drawbacks of solid inorganic peroxides are due to their solubility 
limitations. Calcium peroxide has a solubility of 1.65g/L and due to the production of 




This change in pH can be a problem especially for tissue engineering applications where 
pH change can cause cell death.  
The next part of this study is to assess differentiation on a 3D environment. Previously, 
we have shown that the adipocyte stem cells embedded in the hydrogel were not able to 
differentiate into cardiomyocytes. This supports the idea that while mechanical cues are 
important for differentiation, embedding stem cells in a tissue with mechanical properties 
similar to cardiac tissue is not enough. Therefore, chemical stimulants, 5-azacytidine and 
laminin, were added to the hydrogel formulation and differentiation was assessed. 
Previous research groups have achieved differentiation of human adipocyte stem cells 
into non-beating cardiomyocytes by culturing hASCs in laminin coated wells and 
exposure to 5-azacytidine. This method of differentiation was selected due to the 
simplicity of this method and smooth incorporation into our hydrogel. 
In this study we have investigated the addition of calcium peroxide as a possible 
candidate for in situ oxygen release. Additionally, we investigated the addition of laminin 
and 5-azacytidine in order to differentiate the human adipocyte stem cells embedded in 
the hydrogel into cardiomyocytes.  
5.2.  Materials and Methods 
5.2.1. Sources for Materials. 
Low MW chitosan (50 kDa and 75-85% deacetylation), gelatin type A (100, 175, and 300 
Bloom), β-glycerophosphate (2GP), 50:50 poly lactic-co-glycolic acid (PLGA, 110 kDa), 
polyvinyl alcohol (PVA, 30-70 kDa, 87-90% hydrolyzed), Doxycycline hyclate (DOX, 
pharmaceutical secondary standard), CaO2, 5-azacytidine (catalog no. A1287), 




serum albumin (BSA) were procured from Sigma Aldrich Co (St. Louis, MO).  
Phosphate buffer solution (PBS, pH=7.4), 5-(and-6)-carboxyfluorescein diacetate, 
succinimidyl ester (CFDA-SE) - mixed isomers, StemPro® Human Adipose-Derived 
Stem Cells, MesenPRO RS™ Medium kit, L-glutamine (200 mM, liquid), and powdered 
DMEM low glucose were procured from Life Technologies. (Carlsbad, CA).  Food grade 
Active TI transglutaminase (Enzyme Commission 2.3.2.13) was procured from 
Ajinomoto (Fort Lee, NJ).  Fetal Bovine Serum (catalog no. 30-2020) and Trypsin-EDTA 
was purchased from American Type Culture Collection (ATCC – Manassas, VA).  Fresh 
porcine hearts were purchased from Ralphs Meat Packing Company located in Perkins, 
OK.  Anti-GATA4 antibody (catalog no. ab84593) was purchased from Abcam 
(Cambridge, MA).  Purified anti-human CD105 (catalog no. 323202), FITC Donkey anti-
rabbit IgG (catalog no. 406403), and PE anti-mouse IgG1 (catalog no. 406607) was 
obtained from Biolegend (San Diego, CA).  DAPI Nucleic Stain (catalog no. D1306) was 
purchased from Thermo Scientific Pierce (Waltham, MA).  Cultrex® Mouse Laminin I (1 
mg/mL) catalog no. 3400-010-01 was purchased from Trevigen (Gaithersburg, MD).   
 
5.2.2.  Hydrogel formulation. 
Hydrogel solution was created by previous methods with minor modification (Tormos et 
al., 2015).  In brief, chitosan, gelatin, powdered low glucose DMEM (cat no. 31600-083), 
calcium peroxide, and TG, were prepared in 0.1N HCl (Tormos et al., 2015) according to 
various required conditions.  Solutions were stirred for a minimum of four hours at a 
temperature of 60°C.  After the polymers completely dissolved, solution temperature was 




2GP (4°C) was added drop wise under constant stirring until pH reached biological 
conditions (7.2-7.4).  When Dox was added, DOX-PLGA nanoparticle were filtered 
through a 0.22µm filter and then added to the hydrogel solution and mixed thoroughly.   
 
5.2.3.  Mechanical Characterization.  
Compression tests.  Unconfined compression testing was 
performed on hydrogels using an INSTRON 5542 
(INSTRON, Canton, MA) and a custom-built anvil with a 
diameter of 25mm, as described previously (Tormos et al., 
2015).  In brief, hydrogels were casted in 6-well tissue 
culture plates by incubating 3 mL of solution until 
complete gelation was achieved at 37oC (Figure 5.1).   
Hydrogels were compressed at 1 mm/min crosshead 
speed.  Data were exported to MS Excel and compressive 
modulus was calculated from the slope of the linear 
portion (20% to 40% strain range) of the stress-strain plot. 
Tensile tests.  Tensile tests were also conducted by 
applying the load orthogonal to compression testing to 
ensure uniform cross-linking of the hydrogels, as 
described previously (Tormos et al., 2015).  In brief, 20 
mL of hydrogel solution was prepared in a 35mm petri dish and incubated until complete 
gelation was achieved at 37oC.  After incubation, 10mm × 14 mm × 3 mm rectangular 
slices were cut out and loaded to the Instron 5542 and pulled to break at a crosshead 
 
Figure 5.1. Hydrogel 
samples after gelation. 
 A) 1mL of hydrogel. B) 
0.5mL of hydrogel. C) 3 







speed of 1 mm/min at room temperature. After data collection, stress vs strain was plotted 
and the slope of the linear region, the elastic modulus, was determined.  For all tests, a 
minimum of three experiments were performed per condition from different preparations.   
Stress relaxation experiments.  Hydrogel samples were prepared similar to tensile tests 
were used in these experiments and porcine heart tissue samples were prepared as 
described previously.  Similar dimension (10mm × 14 mm × 3 mm) of porcine heart 
tissues were sliced from the posterior side of the right ventricle while frozen using Chef’s 
Choice® 610.  These samples were subjected to seven successive steps of ramp and hold 
tests.  Each ramp was stretching to 5% at 2.5%/s of the original length.  Each holding was 
for 20 seconds.  Stress was plotted against time.  To understand the effect of each stage 
on the hydrogel, they were normalized by subtracting stress and time elapsed at the 
beginning of each stage.  In addition, reduced relaxation function was calculated to 
understand the amount of stress relaxed in each stage, similar to our previous publications 
(Ratakonda et al., 2012).   
Cyclical tests. Hydrogel samples and porcine heart tissue samples were prepared similar 
to ramp and hold tests described above.  Samples were stretched 10% of their length at a 
speed of 72 cycles per minute and cycles were repeated for 30 min.    
Adhesion tests. In order for this treatment to be successful, the hydrogel must attach to 
the cardiac tissue. To test adhesion to cardiac tissue, porcine cardiac tissue harvested 
from the left ventricle was used.  Hydrogel was added on top of cardiac tissue, followed 
by another identical piece of cardiac tissue (sandwich-like configuration) and allowed to 
gel (Figure 5.2a).  The cardiac tissues were glued to petri dishes to prevent any 




After hydrogel solidified, photographs were taken and the strength of adhesion was 
determined using tensile testing where the top petri dish was taped to an anvil and 
stretched at a speed of 1 mm/min.  Three samples per condition were tested.  After data 
was collected, stress vs strain was determined as before.  
 
5.2.4. 3-D cell culture. 
Human adipocyte stem cells (hASCs) were expanded in MesenPRO RS™ Medium kit, 
following vendor’s protocol.  Cells were maintained at 37°C, 5% CO2/95% air, and fed 
with fresh medium every 2-3 days.  Once confluent, cells were detached with trypsin-
EDTA 1X and then trypsin was neutralized using MesenPRO RS™ Medium.  Cells were 
centrifuged at 210×g for 5 min and dispersed in growth medium.  Viable cells were 
counted using Trypan blue dye exclusion assay. 
hASCs between the passages 3-8 were stained with CFDA-SE, and seeded onto hydrogel 
samples using the procedure previously developed by my laboratory with minor 
 Figure 5.2.  Schematics of experimental setup.  (a). Assembly used for the peel test. 



















modifications(Tormos et al., 2015).  In brief, cells were incubated in growth medium 
containing 2 µM CFDA-SE at 37°C for 20 min followed by washing the excess stain with 
growth medium.  Cells were added to the hydrogel at 0.5×106 cells/mL hydrogel and 
mixed evenly within the solution.  0.5 mL of mixture was then dispensed into the 6-well 
plate and incubated at 37C for until gelation was achieved.  Then, 2mL growth medium 
was added.  After 24 hours, the growth medium was collected for viability via CFDA SE 
analysis and replaced with fresh growth medium.  This process was repeated every 48 
hours until completion of experiment. 
After completion of experiment, cytoplasmic CFDA SE content was extracted from live 
cells by three cycles of freeze and thaw, using the procedure previously reported (Tormos 
et al., 2015).  In brief, cell culture medium was replaced with 2mL PBS and placed at -
20°C until the PBS froze.  After the PBS freezes, the plates were thawed at room 
temperature and cycle was repeated.  Then, the solution was collected and the absorbance 
was determined using a spectrophotometer Gemini XS spectrofluorometer (MDS 
technologies, Santa Clara, CA) at the excitation and emission wavelengths of 485 nm and 
525 nm, respectively.  The CFDA-SE content in the spent medium was also assessed.  
Obtained fluorescence intensities were converted to number of cells using a calibration of 
fluorescence intensity to number of cells obtained as previously described (Tormos et al., 
2015).  
 
5.2.5. 3-D Differentiation 
hASCs (P2-P3) were embedded in hydrogels containing 9µM 5-azacytidine and 2µg of 




hydrogel solution. Each well on a six-well plate contained 0.5mL of hydrogel and cells. 
The hydrogel was allowed to gel and supplemented with growth medium. After 24 hours, 
growth medium was replaced with fresh medium, this was repeated every 48 hours until 
the termination of the experiment at 21 days. At the end of the experiment samples were 
prepared for immunohistochemistry (described in the next section).  
 
5.2.6.  Immunohistochemistry 
After completion of cell culture experiments, some samples were processed for 
cryosectioning.  Samples were submerged in Tissue-Tek® O.C.T. Compound and frozen 
at -20°C.  Samples were sent to Stephenson Cancer Tissue Pathology Core at the 
University of Oklahoma for cryosectioning. Samples were cut at a thickness of 6µm. 
After cryosectioning, slides were prepared for immunohistochemistry. First, using a PAP 
pen a border was drawn around the sample of interest. Next sample was washed with 
PBS to get rid of any leftover OCT.  PBS containing 1% BSA was added in order to 
crosslink any non-specific sites and incubated at room temperature for 30 minutes. After 
30 minutes, slide was rinsed with PBS and primary antibody was added and incubated for 
60 minutes at room temperature.  After 60 minutes, slide was rinsed with PBS and 
secondary antibody was added and incubated for 30 minutes at room temperature. After 
30 minutes, slide was rinsed with PBS and either DAB or DAPI was added and incubated 
at room temperature for 5 minutes.  If DAB was added, after 5 minutes, slide was rinsed 
with PBS and hematoxylin was added and incubated for 15 seconds. After 15 seconds, 
slide was rinsed thoroughly with PBS. Slide was covered with 2-3 drops of cytoseal and a 




captured at representative locations using a CCD camera connected to an inverted 
microscope.   
5.2.7. Forming encapsulated particles of calcium peroxide. 
Embedding of CaO2 was attempted with different protocols listed in Table 1.  Typical 
experimental setup used for the formation of the particles (Figure 5.2b) consisted of 
syringe placed inside an annular area supplied with pressurized air (Madihally and 
Matthew, 1999b).  A list of attempted test conditions is shown in Table 5.1.  In the first 
test, chitosan solution was prepared similar to Section 2.2 and once chitosan was 
dissolved, CaO2 was added.  Chitosan solution was added in a drop-wise manner to the 
bath of NaOH solution.  The second test was similar to the first test except location of 
chitosan solution and NaOH were interchanged; 100 mg of calcium peroxide was added 
into 10 mL of sodium hydroxide solution (2N) and in a drop-wise manner add it to a 
static chitosan solution (variable concentration).  Third and fourth tests were the 
replacement of NaOH with sodium tripolyphosphate (TPP, 25mg/mL) and deionized 
water (DI water), respectively, at different stirring speeds (300 and 1000RPM).  
Table 5.1. List of conditions for formation of CaO2 encapsulated particles. 
Liquid dispensed from the Syringe  Liquid bath in the beaker 
Chitosan with calcium peroxide Sodium hydroxide 
Sodium hydroxide with calcium 
peroxide 
Chitosan 
TPP with calcium peroxide Chitosan 





5.2.8.  Statistical evaluation. 
All experiments were repeated three or more times.  Significant differences between two 
groups were evaluated using a one-way analysis of variance (ANOVA) with 95% 
confidence interval.  When P<0.05, differences were considered to be statistically 
significant. 
5.3.  Results and discussion 
5.3.1.  Impact of calcium peroxide on hydrogel formulation 
As previously stated, it is believed that the lack of oxygen is one of the factors that can 
play a role in the death of cells embedded in the scaffold. The goal of this study is to 
include an oxygen releasing compound to our previously developed hydrogel 
formulation. Calcium peroxide was the chosen oxygen releasing compound in this study. 
However, very quickly it was realized that addition of calcium peroxide would not be 
easy. First it was noticed right away (thanks to the phenol red present in DMEM), that 
addition of calcium peroxide sharply increased the pH of the solution. Since chitosan can 
only dissolve in an acidic environment, an optimal condition was found were calcium 
peroxide was present and did not hinder chitosan from dissolving. That amount was 100 
mg of calcium peroxide for every 100mL of hydrogel solution. While both chitosan and 
calcium peroxide were able to dissolve, it was observed that small oxygen bubbles was 
occurring upon dissolution of calcium peroxide. This is due to the oxygen being released 
as soon as calcium peroxide dissolved. This indicates that calcium peroxide will dissolve 
quickly if the conditions are adequate. This causes a problem because chitosan takes 4 
hours to fully dissolve, therefore, it is believed that by the time the hydrogel solution is 




continued forward with the addition of calcium peroxide and determined the impact that 
the addition of calcium peroxide had on the hydrogel formulation methods. The pH of 
hydrogel solutions with and without calcium peroxide was monitored upon small 
amounts of β-glycerophosphate (2GP) being added. As demonstrated on Table 2, the 
amount of 2GP was decreased by half to reach biological pH (7.2 – 7.4).  




pH of 2% chitosan – 8% 
gelatin – 2% media with TG 
pH of 2% chitosan – 8% gelatin – 2% 
media with TG and CaO2 
0 5.46 ± 0.06 5.98 ± 0.06 
1 6.47 ± 0.09 6.87 ± 0.06  
2 6.85 ± 0.05 7.27 ± 0.03 
3 7.10 ± 0.02  




5.3.2.  Mechanical properties of hydrogels with 
calcium peroxide 
I found that the addition of CaO2 increased the strength 
of the hydrogel compared to a hydrogel without CaO2 
(Figure 5.3). Its compressive modulus increased from 
35.1 ± 2.10 kPa to 41.6 ± 4.07 kPa.  This increase in 
compressive modulus is probably due to less β-
glycerophosphate (2GP) solution used to adjust the pH 
of the solution.  Therefore, the concentration of 
polymers are less diluted.   
Similar to my previous formulations, I conducted relax and hold tests to understand the 
relaxation characteristics.  First, a stress vs time plot showed (Figure 5.4a) that the 
hydrogel was able to withstand the same stress in the tensile mode similar to the cardiac 
tissue.  This is a significant improvement relative to the hydrogels without CaO2, which 
showed less stress accumulation than the cardiac tissue in the tensile mode.  Without 
CaO2, the hydrogel was able to resist less stress and therefore not be as elastic as cardiac 
tissue.  On the other hand, the hydrogel with CaO2 was able to produce more stress and 
 Figure 5.3. Effect of CaO2 
addition on hydrogel 



























 Figure 5.4. Comparison of stress-relaxation behavior between porcine pericardium and 
hydrogel.  (a). Effect of ramp and hold on stress relaxation.  (b) Reduced relaxation 
function for different stages in the 2%8% CG hydrogel with TG and CaO2.  (c).  Reduced relaxation function for porcine pericardium. 
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have a ramp profile similar to cardiac tissue.  Then the relaxation in each stage was 
compared.  In tensile mode, the relaxation in the CG hydrogel varied from 10% to 15%, 
still significantly less compared to cardiac tissue; the percentage relaxation in the first 
stage was 45% in the first stage which decreased to 23% in the cardiac tissue.  The CaO2 
containing samples retained the strain hardening characteristics similar to natural tissues 
including cardiac tissue; the more the material is stretched, the stiffer it gets. 
During the cyclical test, it was confirmed that the hydrogel is able to resist more force 
and produce more stress but it was not close to cardiac tissue (Figure 5.5).  This 
difference in cyclical profile could be due to the hydrogel having randomly aligned 
fibers, whereas cardiac tissue has an aligned structure. 
5.3.4.  Peel Test results 
When hydrogel is injected, it needs to attach to the native tissue.  Hence, I wanted to 
understand the adhesive strength of the hydrogel to the cardiac tissue.  A standard peel 
test (ASTM D903) is used in testing the adhesive strength.  My initial experiments used 
those protocols and tested the samples.  However, during the preparation of those 
samples, one has to use a hook that connects to the cross-head of the tensile testing 
 Figure 5.5. Cyclical behavior between porcine pericardium and hydrogel.  (a) 
Porcine pericardium.  (b) 2%8%CG hydrogel with TG and medium.  Shown are the 
first 20 cycles in each sample.   
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machine.  This significantly weakened the 
test sample.  Hence, I designed a new system 
that required no hook to be used.  Maximum 
stress was 1.45 ± 0.19 kPa, which is slightly 
stronger that the commercially available 
fibrin adhesive (Tisseel®) (McDermott et al., 
2004) (Figure 5.6).  This suggests that the 
hydrogel could be used in the cardiac regeneration.  If additional strength is required, one 
could increase the concentration of TG, as currently used concentration of TG in the 
hydrogel is 10X less than the recommended level (Broderick et al., 2005).   
This adhesion test was conducted on a static harvested sample where as an in vivo setting 
other variables need to be considered.  I attempted to attach this hydrogel to a rat’s heart 
in an ex vivo setting.  The heart was kept beating by pumping calcium buffer through the 
heart.  However, the flow of the buffer caused a boundary layer outside the heart and the 
hydrogel could not attach. There is a chance that the hydrogel might still attach while in 
an in vivo setting due to chitosan being a blood 
clotting agent. On the other hand, depending on 
the formation of blood clots can lead to further 
complication.  
5.3.5.  Viability of hASCs with CaO2 
First, viability of stem cells after three weeks 
was assessed due to long-term exposure of 5-
azacytidine, which reports have shown to be 
 Figure 5.7.  Effect of additives 
on hASC recovery from the 
hydrogel during 21-day 



















 Figure 5.6. Strength of adhesion of 
hydrogel to the pericardium. Stress-
strain curve showing the break point. 














toxic at high and prolonged concentrations. Hydrogels containing TG showed an 
approximate 10% decrease in cell viability for all time periods. This could be a direct 
result of long term exposure to 5-azacytidine. Furthermore, addition of calcium peroxide 
seemed to decrease viability even more. Figure 5.7 shows that the addition of calcium 
peroxide alone decreases viability to 60% at the end of three weeks. The combinations of 
calcium peroxide and 5-azacytidine further decrease the viability to 50%. This loss in cell 
viability could be due to chelation. Chelation of calcium ions may reduce TG 
crosslinking between chitosan chains, ultimately decreasing the stability of the hydrogel.  
5.3.6.  3D Differentiation 
qPCR was expected to be used to support immunohistochemical evidence of however, 
hydrogels were not able to degrade and isolation of quality cell and/or RNA was not 
achieved. As previously shown, exposure to proteolytic enzyme Trypsin, did not degrade 
the hydrogels (Tormos et al., 2015). 5-azacytidine and laminin were included in the 
hydrogel formulation to assess whether differentiation can occur in a 3D environment. At 
the end of 21 days, presence of hASC markers confirm that hASCs did not differentiate 
regardless if they were exposed to 5-azacytidine and laminin or not (Figure 5.8). 
Furthermore, lack of cardiac markers also confirm that differentiation did not occur. In 
addition, structure of hydrogels is clearly very different than as observed on Chapter IV. 
While TG and doxycycline improved stability by increased crosslinking, at the end of 21 





5.3.7.  Formation of particles 
It is believed that most of the oxygen is being burst-released prior to in vitro experiments. 
Therefore, similar to our controlled release of doxycycline, calcium peroxide was 
entrapped in chitosan nanoparticles. PLGA nanoparticles have a slow degradation rate, 
therefore a polymer that degrades faster was chosen. Chitosan particles have been 
previously used to entrap proteins and their release is applicable to our needs. Back on 
table 1, different conditions were listed for the formation of chitosan particles embedding 
 Figure 5.8. Effect of CaO2, laminin +5-Azacytidine on the differentiation of hASCs 




calcium peroxide. First, a larger amount of 
calcium peroxide (1 gram compared to 100 
mg) was added to 100mL of a 2% (w/v) 
chitosan solution. The calcium peroxide that 
was added formed a “blob” of chitosan 
peroxide and would not dissolve or even 
spread out in the chitosan solution (Figure 
5.9a). Even when added as a high 
concentrated solution, calcium peroxide did 
not spread and dissolve (Figure 5.9b). Therefore, it was decided to switch the 
experimental setup and have basic solution with calcium peroxide being added to 
chitosan solution. Addition of a 1% (w/v) of calcium peroxide in sodium hydroxide (2N) 
to a 2% (w/v) chitosan solution was attempted (Figure 5.9a). This resulted in large 
particles (6.44 ± 0.57 mm) with an inside diameter of 4.41 ± 0.24 mm that are not able to 
precipitate. While particles were obtained, isolation was not possible. If particles were 
centrifuged, they would lose their shape and flatten out. If particles were scooped out 
using a spatula, they also lost their shaped upon removal from chitosan solution. It was 
then decided that sodium hydroxide might not be the optimal condition for making 
chitosan particles. Next, sodium hydroxide was replaced with sodium tripolyphosphate 
(TPP) at a concentration of 25mg/mL. TPP has been previously used to make chitosan 
nanoparticles. Due the lack of detail provided on methods including chitosan and TPP, 
Figure 5.9 Addition of calcium 
peroxide to chitosan solution. (a) In 




several experimental conditions were attempted.  First, a 1% CaO2 solution in TPP was 
added to a 2% chitosan solution with no stirring. No precipitation was observed for these 
conditions. Next, chitosan was diluted to 1% (w/v) and while precipitation was observed 
particle formation was not instant and therefore the CaO2 spread all over the solution 
forming blobs similar to previous experiments. Chitosan was further diluted but the same 
problem persisted (Figure 5.10b). Then we decided to take advantage of the blob 
formation and use it to surround the CaO2 with chitosan and then expose it to NaOH to 
create a precipitation layer encapsulating the CaO2. Addition of 1% (w/v) CaO2 in DI 
 Figure 5.10. Effect of encapsulation process on particle formation.  (a) Condition #2. 
A 10 mL syringe was loaded with a 1% solution of calcium peroxide (w/v) in sodium 
hydroxide (1M) and a 14 gage needle was used to release the solution in a drop-wise 
manner to a 2%chitosan solution (w/v). (b) Condition #3, a 10 mL syringe was loaded 
with a 1% solution of calcium peroxide in TPP (25mg/mL) (w/v) and a 14 gage 
needle was used to release the solution in a drop-wise manner to a 0.25% chitosan 
solution (w/v).  (c) Condition #4, a 10 mL syringe was loaded with a 1% solution of 
calcium peroxide (w/v) in deionized water and a 14 gage needle was used to release 
the solution in a drop-wise manner to a 2.0 %chitosan solution (w/v). (d) Condition 
#4 after 10 minutes. (e) Condition #4 after 24 hours. (f) Condition #4 upon addition 
of DI to wash excess chitosan, followed by addition of NaOH (2M) and 5 minutes of 
incubation at room temperature, followed by 3 washes of DI water to wash off any 
excess NaOH. (g) Incubation of chitosan particles in PBS at room temperature after 2 
hours. (h) Condition #4 upon addition of sodium hydroxide (2M), followed by 3 
washes of DI water. (i) Incubation of chitosan particles in PBS at room temperature 




water was done without stirring due to aggregation of droplets (Figure 5.10c). CaO2 
droplets were dispersed in a petri dish containing 2% (w/v) chitosan solution. Initially, no 
distinction could be made from an inner and outer diameter, however, after 10 minutes 
the distinction became clear (Figure 5.10d).  After 24 hours, the DI water had dispersed 
and only spherical aggregates of CaO2 remained (Figure 5.10e).  Aggregates were 
submerged to ensure complete chitosan engulfing. With a spatula, CaO2 aggregates were 
isolated and placed in a clean petri dish. Next, 2 paths were taken. First the aggregates 
were washed with DI water to remove excess chitosan, followed by an addition of 2N 
NaOH for 5 minutes (to induce precipitation), and finally 3 washes of DI water to 
neutralize any NaOH present (Figure 5.10f-g).  The other path was similar except there 
was no removal of excess chitosan (Figure 5.10h-i).  While both path resulted in chitosan 
particles, those without the pre-wash of DI water released oxygen faster, evident by 
floating particles. 
5.4 Summary 
In this study, the addition of calcium peroxide to the hydrogel formulation to serve as the 
oxygen releasing compound was investigated. The addition of CaO2 had positive and 
negative effects on the hydrogel’s performance. On the positive side, CaO2 increased 
linear mechanical properties and brought the mechanical properties of the hydrogel 
similar to cardiac tissue. In addition, it improved the cyclical properties of the hydrogel 
however, it is still far away from cardiac tissue. On the negative side, CaO2 decreases 
hASC viability. Cell viability is incredibly critical and therefore any changes in hydrogel 
formulation that decreases viability should be eliminated. Furthermore, the addition of 




days regardless of whether the cells were exposed to 5-azacytidine and laminin. Since 
oxygen is limited in a necrotic environment, encapsulation of CaO2 was investigated. 
Encapsulation of CaO2 was unsuccessful despite various and different encapsulation 
methods. This is believed to be due to the gelation method of the encapsulation methods 
attempted. The gelation method or formation of particles of these methods are slow and 
take time, which gives enough time for CaO2 to dissolve and release the oxygen. 
Therefore, it is recommended for other encapsulation methods to be attempted as long as 
particle formation occurs instantaneously and calcium peroxide is dispersed in an organic 











The goal of this study was to investigate a chitosan-gelatin hydrogel as a suitable 
candidate for cardiac tissue repair and regeneration for patients who have experienced a 
heart attack.  Researchers are working on developing cells based therapies to repair the 
damage using stem cells (Behfar et al., 2014, Campbell and Suzuki, 2012, Garbern and 
Lee, 2013, Segers and Lee, 2008). However, stem cells alone cannot repair the tissue 
alone.  Studies have shown that an injection of stem cells to the damaged region is not 
successful because the majority of the implanted cells (~90%) die within 1 week (Behfar 
et al., 2014, Menasche, 2011a, Segers and Lee, 2008).  Cell death is hypothesized to be 
caused by lack distribution of cells, lack of nutrients, and lack of oxygen. However, even 
with the addition of biomaterials, improvement in cell survival upon delivery was 
minimal (Hong et al., 2007).  While the addition of biomaterials resolved the issue of lack 
of distribution, it added more problems.  Problems that are associated with the addition of 
biomaterials include: stability of material, immune reaction by the host, and mechanical 




addresses the issues of lack of nutrients, lack of oxygen, material stability, mechanical 
property compatibility, and immune reaction by the host.  To address these challenges I 
decided to split the project into three aims. Aim 1 was to investigate the behavior of the 
developed hydrogel when exposed to forces similar to what cardiac tissue experiences.  
Results addressing this aim are presented in Chapter III and Chapter IV and a conclusion 
regarding this aim is available on section 6.1.1 Aim 2: was to improve the survival of 
hASCs after application.  Results addressing this aim are presented in Chapter IV and 
Chapter V and a conclusion of this aim is available on section 6.1.2. Aim 3 was to 
evaluate cardiomyogenesis of hASCs in a 3-D environment.  Results addressing this aim 
are presented in Chapter IV and Chapter V and a conclusion regarding this aim is 
available on section 6.1.3.  
6.1.1 Aim 1: To develop hydrogel that can withstand wound healing environment 
and improve cell survival 
I explored the possibility of stabilizing the chitosan-gelatin (CG) injectable hydrogels 
using i) controlled release of doxycycline (DOX) to prevent premature degradation due to 
increased gelatinase activity (MMP-2 and MMP-9), and ii) transglutaminase (TG) to in 
situ cross-link gelatin to improve the mechanical stability.   
The release profile analyzed by a single compartment modeling showed that 90% of 
DOX released from cross-linked CG hydrogels after four days, unlike CG hydrogels 
where 90% of DOX was released within the first day.   
Addition of TG enhanced the CG hydrogel stability significantly. DOX can be released in 
a controlled manner using CG cross-linked with TG.  Addition of TG and media 




CG cross-linked with TG showed significant improvement in the retention of human 
foreskin fibroblasts (hFF-1) cultures at day 5; cells recovered from CG-TG was 2.5 times 
more than that collected from CG with DOX release.  There was inhibition of MMP-
2/MMP-9 activity, directly correlating cause and effect of DOX release levels and 
improvement in hydrogel stability, which further helped cell retention.   More than 60% 
of seeded fibroblasts were recovered from the CG-TG hydrogels at day 5, unlike 40% 
recovered from CG-hydrogels.  Inhibition of MMP-2/MMP-9 were observed.  Improved 
retention of cells holds promise in using the CG-based cell delivery to repair tissues. 
6.1.2 Aim 2: To improve the survival of hASCs after application and evaluate 3D 
differentiation.   
I determined the optimal hydrogel formulation by exploring different types of gelatin and 
chitosan, and by varying the concentration of gelatin, growth medium, and 
transglutaminase.  The optimal concentration was determined by comparison of 
mechanical properties between hydrogel and porcine cardiac tissue.  The optimal 
formulation included 2% (w/v) chitosan, 8% (w/v) gelatin, 2% (w/v) growth medium, 
0.03% (w/v) transglutaminase, and 0.1% (w/v) calcium peroxide.  With this formulation, 
compressive modulus of the hydrogel was the closest to porcine cardiac tissue. In terms 
of cyclical properties, this formulation was also optimal for cardiac tissue regeneration.  
During the relax and hold test, the optimal hydrogel had similar relaxation profile to 
cardiac tissue.  On the other hand, cyclical profile did not appear similar but hydrogel 
was able to withstand up to 30 minutes of continuous testing. 
Differentiation of hASCs into cardiomyocytes was first attempted in 2-D and then 




azacytidine for 21 days, while exposure to PMA for 9 days was not successful.  Laminin 
and 5-azacytidine was included in the hydrogel formulation to induce differentiation.   
More than 80% of seeded hASC were recovered from the CG-TG hydrogels at day 21.  
However, evaluated differentiation markers suggested that hASCs did not differentiate.  
Presence of Laminin and 5-azacytidine decreased cell viability. 
6.1.3 Aim 3: To add oxygen releasing component in hydrogel formulation and 
investigate hydrogel’s differentiation ability and mechanical properties.  
Calcium peroxide (CaO2), an oxygen releasing molecule was added to the hydrogel 
formulation to further increase cell viability.  Optimal hydrogel formulation was explored 
by altering CaO2 and 2-glycerolophosphate, which is used to adjust pH required for 
thermosensitive gelation of chitosan hydrogel.  The mechanical properties were improved 
by addition of calcium peroxide both linear and nonlinear properties.   
With this formulation, mechanical properties of the hydrogel improved further, reaching 
that of porcine cardiac tissue.  In terms of cyclical properties, this formulation was also 
optimal for cardiac tissue regeneration.  During the relax and hold test, the optimal 
hydrogel had similar relaxation profile to cardiac tissue.  However, stress-strain profiles 
in cyclical conditions did not appear similar but hydrogel was able to withstand up to 30 
minutes of continuous testing. 
Most of the oxygen was released prior to cell culture experiment and cell viability 
decreased.  Since direct addition of CaO2 resulted in burst release of oxygen, I attempted 
to encapsulate CaO2 in chitosan particles. Encapsulation was unsuccessful due to several 




Differentiation of hASCs was assessed and evidence of differentiation was not found. 
Presence of CaO2 decreased cell viability.  However, evaluated differentiation markers 
suggested that hASCs did not differentiate.   
6.2 Future Studies 
Based on the experience of these findings, I believe few of the relevant issues listed 
below should be addressed to advance this research.  
6.2.1. Time of gelation 
Valid production of 2 % (wt/v) chitosan and 8% (wt/v) gelatin hydrogels is somewhat 
inconsistent and prone to premature gelation.  This is believed to be due to the high 
content of gelatin.  Gelatin starts to gel at room temperature, resulting in premature 
gelation.  To counter this problem, one could explore two options: 
i) decrease gelatin content and increase chitosan content, and  
ii) substitute gelatin for decellularized cardiac tissue.  
Addition of more binding domains such as addition of RGD peptide. Modification of 
chitosan by adding RGD peptide to backbone of chitosan. 
6.2.2. Differentiation of hASCs in a 3D environment 
Differentiation of human adipocyte stem cells is somewhat inconsistent. As presented in 
chapter 4, different methods were attempted but only one succeeded.  Even 5-azacytidine 
(the method that succeeded) was inconsistent at times similar to previous reports (Wan 
Safwani et al., 2012).  I recommend to explore additional stimulation in order to provide 
a more consistent differentiation protocol.  For example, mechanical contraction of 




induce differentiation (Black et al., 2009, Happe and Engler, 2016). Another stimulation 
that can be investigated is the presence of electrical pulses similar to what the cardiac 
tissue experiences (Pijnappels et al., 2008). An additional option, is to induce 
differentiation of hASCs by inhibition of mRNA. Another option is to culture primary 
human cardiomyocytes on tissue culture plates, collect the waste media, and use the 
waste media to feed hASCs. This media can even be freeze dried into a powder and used 
as a replacement for DMEM in the hydrogel formulation. The idea behind this 
experiment is that by culturing cardiomyocytes they will secrete signals to promote 
growth and proliferation which for stem cells might be signals for differentiation. Finally, 
another recommendation is to co-culture human cardiomyocytes with hASCs and assess 
whether differentiation occurred (Bollini et al., 2011, Choi et al., 2010, Hussain et al., 
2013). 
6.2.3. Use of other stem cell sources 
Alternatively, one could explore another source of stem cells or cardiomyocytes.  For 
example, recently a population of cardiac stem cells has been discovered (Bearzi et al., 
2007).  While protocols for successful isolation and a high yield percentage are still being 
discovered, this source could become a much better option and might need very little 
stimulation to differentiate into cardiac cells.  Another source of stem cells is to use 
induced pluripotent stem cells and differentiate them into cardiomyocytes like others 
have done (Fujiwara et al., 2011).  Finally, there is a commercially available source of 




6.2.4 Further delivery of oxygen and nutrients 
Calcium peroxide encapsulation was unsuccessful with the protocols listed on Chapter V. 
However, that doesn’t mean that it can’t be done.  I believe that encapsulation of calcium 
peroxide can be successful using a hydrophobic solvent and with a particle formation that 
is instantaneous.  When particles are form instantaneous it doesn’t allow for calcium 
peroxide to precipitate nor to dissolve while the particle is forming.  Using the current 
formulation the hydrogel must be tested in an in vivo setting and assess how fast do blood 
vessel start to form.  The DMEM provided in the hydrogel will not last long and cells 
need a constant source of nutrients which can be provided be the newly formed blood 
vessels.  If blood vessel formation is to slow, I suggest adding growth factors such as 
FGF, VEGF, Ang1, Ang2, PDGF, etc. 
6.2.5 Co-culture of stem cells with endothelial, smooth vascular, myofibroblasts 
One could investigate whether this hydrogel can support multiple cell lines including 
cardiomyocytes, endothelial cells, smooth vascular cells, and myofibroblasts (Menasche, 
2011b). Furthermore, it will be beneficial to investigate whether this hydrogel supports 
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